university of wisconsin comprehensive cancer center · the prevention and cure of cancer. ... the...

A N N U A L R E P O R T 2 0 0 0 - 2 0 0 1

University of Wisconsin

ComprehensiveCancer Center

NCICCC®

INSIDE

Message From the Director 1

Duane Gay and the Endostatin Phase I Study 2-3

Cancer Clinics Expansion 4

The Best Cancer Care 5

Outreach and Education 6

Cancer Connect and Cancer Information Service 7

Cancer Control and Population Science 8-9

Cancer Genetics 10-11

Cell Signaling andGrowth Control 12-13

Etiology and Chemoprevention 14-15

Experimental Therapeutics 16-17

Human Cancer Virology 18-19

Imaging and Radiation 20-21

Immunology andImmunotherapy 22-23

Leadership 24

Members 25

Donors and Gifts 26-34

In Memory of E. Gregory MacEwen 27

Financial Data 34-35

Contribution Information 36

TDear Friends,

This past year was marked not only bysignificant individual achievements, butalso by the completion of the consolidationof the University of Wisconsin-Madison’stwo distinguished cancer centers—the McArdle Laboratory for CancerResearch and the UW ComprehensiveCancer Center (UWCCC).

During the 2000-2001 academic year, thetwo centers essentially functioned as the“new” UWCCC. The Center is based oneight research programs, which aredescribed on pages 8-23 in this report. Webelieve this structure optimizes intra- andinter-programmatic research and markedlyfacilitates the efforts to apply ourdiscoveries to improving the care of ourpatients with cancer.

Be sure to read more about Duane Gay, aMilwaukee TV newscaster, and hisinvolvement in the highly-publicizedEndostatin clinical trial on pages 2-3. TheUWCCC was one of just three centersselected to study this new drug and wasquite honored to be nationally featured onthe PBS series NOVA this past March inrelation to the clinical trial.

The close relationship between the UWCCCand UW Hospital and Clinics gives patientsaccess to outstanding clinicians, whosefocus is on the best care for patients,research, education, and prevention. UW Hospital and Clinics ranked among thetop three percent of the nation’s majormedical centers in the recent edition of

U.S. News and World Report’s “America’sBest Hospitals”—with high recognition inthe cancer arena.

The UWCCC’s outreach and education staffcontinues to provide a bridge between newresearch discoveries and their applicationin the community. Our staff reaches out tocancer patients and their families as well ashealth care professionals to provide themwith information, educational programs,resources and technical assistance.

We recognize that this is not a time for restand accolades. Instead we must rededicateourselves to move rapidly forward with arenewed spirit and commitment to thecontinued growth of the areas of researchand teaching that will be of highimportance in the upcoming decade.

As we move beyond the sequencing of thehuman genome, advances in the biologicalsciences promise to deeply impact ourunderstanding of cancer, as well astransform the very nature of cancerresearch itself and the way in which wetreat our patients. Without doubt, cancerwill be the principle target of theserevolutionary changes, and the nationaleconomy (both federal and industrial) willbe directed toward discovery in the lifesciences. It is imperative that the UWCCCposition itself to be of major assistance toUW-Madison and the State of Wisconsin inmeeting these challenges. There will be farreaching effects on economy, technology,and society through ethical issues andeducation.

I believe we have a clear vision for thefuture and of the challenges ahead. I hopethis report provides insight into thetremendous potential of the Center’s facultyand of the future for achieving our goal ofthe prevention and cure of cancer.

On behalf of our faculty and theindividuals and families who benefit fromtheir work, I thank you for your support ofthe UW Comprehensive Cancer Center.

Sincerely,

John E. Niederhuber, MD, Director UW Comprehensive Cancer Center

1UW Comprehensive Cancer CenterAnnual Report 2000-2001

Message from the director,John E. Niederhuber, M.D.

FFinding better ways to treat—andultimately, cure—cancer is, bydefinition, what fuels the engine we callclinical research. As one of 40 NCI-designated comprehensive cancer centersin the nation, the University of WisconsinComprehensive Cancer Center (UWCCC)brings literally hundreds of the greatestminds to the cancer research table.

Advances in cancer research, however,would not be possible without the timeand commitment of cancer patients whochoose to participate in clinical trials.Many patients travel from distantlocations for treatments that offer noguarantees. And yet, they often feelprivileged to serve on the front lines ofthe war on cancer.

One such soldier is Duane Gay, 45, aveteran television news reporter onMilwaukee’s WISN-TV Channel 12. As anewsman and cancer patient, Duane hadbeen doing a lot of research about anapproach to cancer treatment thatsuggests that tumors can be starved bycutting off their blood supply. Thisapproach, known as angiogenesisinhibition, has for decades beenassociated with the work of Dr. JudahFolkman of Harvard Medical School andChildren’s Hospital of Boston. If provedsuccessful in clinical trials, angiogenisisinhibitors would be viewed as a verysignificant medical advance. Not onlymight a cancer be more effectivelycontrolled, but patients would notexperience the same degree of toxic sideeffects often associated with conventionalchemotherapy or radiation therapy.

A naturally occurring protein, Endostatinhad been shown to cut off the bloodsupply to tumors in mice, but would it do

the same in human patients? With muchof the oncology world watching, theUWCCC was selected in 1999 as one ofonly three cancer centers at which thisdrug would first be given to humans.

As the phase I clinical trial of Endostatinwas getting underway, Duane Gay wasreporting to Milwaukee television viewersabout a Chicago-area man who wascommuting to Madison as an Endostatinpatient. Duane was hoping he wouldultimately qualify for the drug himself,but initially he did not meet all of thestudy’s criteria. Just three months later,however, circumstances had changedenough to qualify Duane for the study.For six months—from June to December2000—he made the 160-mile round tripfrom Milwaukee to Madison seven days aweek for his one-hour infusion ofEndostatin. Moreover, he did so knowingthat the primary goal of a phase I trial isto determine a drug’s safe dosage, notgauge effectiveness.

“My first cancer experience was actually10 years ago,” Duane remembers. “I hada soft-tissue sarcoma removed from mylower abdomen that we thought wascontained. And, for seven years, I wascancer-free.”

Then on August 31, 1997—the day oftheir first wedding anniversary—Duaneand Teri learned some devastating news.

“I had been anchoring the morningnews and I was having shortness ofbreath,” Duane says. “I went in and afterthe X-rays and the CT scans were lookedat, they found 39 tumors in my lungsand more in my liver. It was the samesoft-tissue sarcoma from the first timeand it was back.”

MARCH 1999 UWCCC chosen as a one of

three sites for the first phase I Endostatin clinical trial on

human patients

DECEMBER 1999 First UWCCC patients begin

receiving Endostatin

JUNE 2000Duane Gay selected as a patient in

the UWCCC Endostatin study

NOVEMBER 2000Preliminary results presented at

international cancer researchconference show that all patients

tolerated Endostatin very well

DECEMBER 2000Duane Gay leaves UWCCC

Endostatin study

SPRING 2001Duane Gay continues treatment at

UWCCC under care of Howard Bailey, M.D.

SUMMER 2001Last of 21 UWCCC Endostatin study

patients leaves study

Further basic and clinical research on Endostatin and

other angiogenesis inhibitorscontinues at UWCCC

Duane Gay:A soldierin the front lines against

DUANE GAY AND THE ENDOSTATIN PHASE I

STUDY AT THE UWCCC

After initially being told there was nothingthat could be done, Duane ultimately went through major surgery on both lungsand his liver, separated by several monthsof chemotherapy. For a while, the tumorswere kept at bay. Eventually, however, they returned, leaving Duane with very few options.

Duane and Teri struggled at times with theimpact of Duane’s diagnosis on the fragilestate of their young marriage.

“A new bride doesn’t need this thrown inher lap before the marriage gets a chanceto take off,” Duane says, recalling the verybad news that came on their firstanniversary. “When we got this news, Ifound myself pulling away from Teri. Atsome level, I assumed I was going to dieand I thought it would be not as hard onher if I kind of pulled away emotionally. Ididn’t want us to fall more deeply in loveso that the blow would be harder.”

Ultimately, Duane and Teri decided toapproach Duane’s disease as a team.Through that kind of collaboration, theylearned a lot about Dr. Folkman, angio-genesis and the prospect of having anEndostatin clinical trial site located just 80 miles from home—at the UWCCC in Madison.

“When I was on the Endostatin trial,people said, ‘Isn’t that a hassle to go toMadison every day?’ ” recalls Duane. “Myresponse was that I thanked the Lord everyday that I was as close as I was to thisfacility with all the great minds workinghere on the research for new treatmentsand cure for this horrible disease.”

Although Duane had to leave the phase IEndostatin trial in December 2000 becauseone of his tumors grew beyond the study’s

limits, he is currently continuing a series oftreatments designed to keep his cancerunder control.

“Patients such as Duane really are the trueheroes in the fight against cancer,” says hisUWCCC physician, Howard Bailey, M.D. “It is because of their willingness to tryexciting, yet unproven cancer drugs in thehope of helping not only themselves but somany others down the road that we makeprogress.”

Duane carefully walks the fine line betweenhope and reality as he reflects on where hehas been and what lies ahead.

“Of course I am fighting for my life, butalong the way, this is a war and it has beengoing on for generations,” Duane says. “Ijust have this feeling that we are gettingclose to victory and that when they figure

out how to use it, Endostatin or a drug likeit could be the key to unlock some of themystery in cancer.”

Duane no longer lets a single day passwithout acknowledging its beauty. A self-described workaholic until his cancerreturned in 1997, Duane’s priorities arevery different nowadays.

“In the last three years, I have lived morethan I did in the previous 40,” he says. “Iremember starting a talk by saying, ‘I wishall of you could be told you have cancer.’After a loud gasp in the room, I quicklyadded that while I would hope these peopledid not really have cancer, there is nothinglike a cancer diagnosis that brings homelife’s finite nature and might help some ofus change the way we live.”

Cancer


As one of the first human patients on the phase I clinical trial ofEndostatin, Duane Gay (left) received daily one-hour infusions of the drugfor six months at the UW Comprehensive Cancer Center. Attending toDuane are James P. Thomas, M.D., principal investigator of the UWCCCEndostatin trial, and Jennifer Kahl, R.N., phase I clinical research nurse.

OOur commitment is to provide thehighest standard of cancer careavailable.

In order to serve the needs of the growing number of patients as well as provide spacefor enhanced services, the CancerCenter at UW Hospital and Clinicsannounced plans in 2000 toexpand its current CancerClinics space and to build anew Breast Center.

With patients and familymembers clearly the focus, this90,900 square foot expansion willinclude the Cancer Clinics (13,100 sq.ft.), the Breast Center (9,000 sq. ft.),Radiology (22,000 sq. ft.) and space forfuture growth.

According to Teresa Smith, Director ofOncology at UW Hospital and Clinics,“Our new space will warmly welcomepatients and loved ones who are dealingwith all aspects of cancer. We realize thisis a stressful time for patients, and we aretrying to provide a comfortableenvironment for our care to take place.”

Scheduled to be completed in late fall2002, the Cancer Clinics expansion willinclude:

• Expansion of the chemotherapy areafrom 20 to 34 bays

• Expansion of exam space from 22 to 31 exam rooms

• Expansion of the oncology pharmacyto include new retail pharmacy space

• Additional patient support and edu-cation space & new lab drawing space

• “Friends” wig program

The Development of a Breast Center willbring together the clinical and imagingservices needed to better serve individualswith breast problems. The Center willinclude both screening services as well asdiagnostic services.

The Breast Center will feature:• Mammography (2 digital mammo-

graphy units & 2 standardmammography units)

• Stereotactic breast biopsy (a newservice)

• Fine needle aspiration• Image guided biopsy• Breast ultrasound• Multidisciplinary consultation and

second opinion service• Long-term breast evaluation and

breast follow-up clinics• Genetics-risk assessment and

counseling• Clinical research • Patient library and increased patient

education space• Volunteer services

Expanding to meet Cancer’s Challenge

EExceptional cancer care begins withexceptional physicians and staff.

The Cancer Center at UW Hospital andClinics gathers the knowledge ofoutstanding health professionals whounderstand treating cancer is more thanmanaging a disease: it is caringcompassionately for people. Located in ateaching hospital, we are at the heart ofmodern academic medicine and the mainsource of new treatments and techniques.

Cancer is a complex disease that requires acomplex response. With clinicians andresearchers working together, we have theability to rapidly translate the latest scien-tific discoveries into today’s patient care.

Our strength continues to lie in our“multidisciplinary” Cancer Clinics where amedical oncologist, radiation oncologistand surgeon all work together indetermining the best possible treatment foreach patient. Our Cancer Clinicsincorporate several disciplines in order toenhance patient care, includingoutstanding nursing, genetic counseling,social work, pathology, radiology,psychology and dietary evaluation.

Most importantly these clinics are closelylinked with the Center’s groundbreakingresearch laboratories. The same physicianswho provide this excellent patient care areinvolved in research projects aimed at thecure of cancer (see pages 8-23).

For more informationFor more information on our CancerClinics, please view our website,www.cancer.wisc.edu or call 1-800-622-8922.

Multidisciplinary Cancer Clinics include:• Brain tumor• Breast• Esophageal• Gastrointestinal oncology• Gynecologic oncology• Head and neck• Lung• Lymphoma• Melanoma• Pain and palliative care• Pediatric hematology/oncology• Urology


Providing theBest Cancer Care

Jane Schiefelbein (right), a patient in the UWCCC gynecologic oncologyclinic, discusses her treatment plan with Ellen Hartenbach, MD (left) andRobin Christianson, RN.

UW Hospital and Clinics—Comprehensive Cancer Center2000 Cancer StatisticsTotal unique patients (outpatient and inpatient) 12,418

New cancer cases 2,962

Outpatient visits 68,409

Inpatient discharges 3,318

Inquiries to Cancer Connect 3,600

REACHING OUT TO THE COMMUNITY

KIDS, CANCER AND FAMILIESKelly Saxby, 4, of Windsor, Wisconsin(right), participates in an art activityat the Kids, Cancer and Familiesevent last May as teen volunteerDarcy Johnson of DeForest,Wisconsin, assists her. Kelly has arare form of cancer known asBurkitt’s Lymphoma.

WISCONSIN CANCER COUNCILThe Wisconsin Cancer Council,formed in 1985 by the UWCCC, is acoalition of 60 members,representing 28 organizations fromthroughout the state, who arededicated to reducing the incidenceand mortality of cancer in Wisconsin.

Recent Council initiatives havefocused on health insurance benefitchanges for state employees toinclude tobacco cessation costs,ways to increase access andrecruitment to clinical trials,information to health professionalson availability of cancer geneticscounselors, and participating in thepublic health planning processthrough the State’s “Turning Point”initiative.

Outreach andEducation

AAn integral part of the UW ComprehensiveCancer Center’s mission is fostering anenvironment that promotes life-longlearning for our patients, our communityand our many healthcare partners.

The Cancer Center’s programs andservices provide the residents of southcentral Wisconsin, as well as thoseoutside of the region, with outstandingeducational resources. During the pastyear, our focus has included thefollowing:

Breast Cancer Education.Developed in 1999, Meet Me AboutBreast Cancer was started to meet thespecific needs of medically underservedand minority women. This program hasbeen presented in English, Spanish andRussian to women in Dane County.Additionally last year, 21 lay healtheducators—Breast Health Ambassadors—were trained to present early breastcancer detection programs to rural DaneCounty women. Together these twoprograms have been presented to morethan 500 women. Based on the lay healtheducator model, a breast health programfor the Latina community in southcentral Wisconsin began in 2001.

American Indian LeadershipInitiative. The North Central CancerInformation Service (CIS) and theCancer Center have partnered with theMayo Cancer Center on a nationwideinitiative to improve cancer outcomesamong American Indian/Alaska Nativepopulations in five states (Wisconsin,Minnesota, Iowa, North Dakota andSouth Dakota). Highlights have includedvisits to 11 tribal health departments andclinics, technical assistance to the Ho-Chunk Men’s Cancer Awareness Project,

development and implementation ofthree tribal cancer education trainingseminars and technical assistance on amulti-state cancer seminar for Aberdeenarea Community Health Representatives.

Share the Care. In the spring of 2001,the Cancer Center introduced a programto educate health care professionals,clergy, and the community about Sharethe Care. Share the Care offers a uniquegroup approach that can turn a circle ofordinary people into a powerful caregiverteam for an individual with a seriousillness. It shows how to create a caregiver“family” for those individuals who maynot have a strong support system.

The UW Comprehensive Cancer Center has partnered with several state, nationaland international organizations toprovide them with technical assistanceand resources. A few of our keypartnerships include:

• American Alliance of Cancer PainInitiatives

• Mayo Cancer Center

• Pain and Policy Studies Group

• UW Center for Tobacco Research andIntervention

• Wisconsin Cancer Council

• Wisconsin Department of Health andFamily Services

• World Health Organization

For more informationFor more information about CancerControl and Outreach, please view theCancer Center’s website,www.cancer.wisc.edu or call our Cancer Control and Outreach office, (608) 263-2212.

LLearning that you or a loved one hascancer can be devastating. What follows isalso daunting: understanding yourhealthcare system and how it works, siftingthrough information about your disease,and knowing what local, regional andnational resources are available to you.

CANCER CONNECTCancer Connect serves our patients and thegeneral public in learning more aboutspecific diseases, options for treatment, andclinical trial opportunities at the UWCCC.Staffed by skilled oncology healtheducators and nurses, Cancer Connecthelps people understand the range ofservices and programs available at theUWCCC.

Additionally, Cancer Connect professionalswork directly with physicians and otherhealth care providers to assist withcommunications, referrals andappointment scheduling with UWCCCspecialists.

Established in September 1998, CancerConnect has responded to over 9,200inquiries, with more than 3,600 inquiriesin 2000. During the past year, CancerConnect has worked in redesigning andmaintaining the Cancer Center’s website,developing a chemotherapy teaching videofor patients, and teaching patients andfamily members how to use the newCancerHelp Touchscreen computer in theCancer Clinics.

For more informationPhone (608) 262-5223 (In Madison)

or 1-800-622-8922

E-mail [email protected]

Hours 9 a.m.-4 p.m. (Monday-Friday)

Web Site www.cancer.wisc.edu

CANCER INFORMATION SERVICEThe Cancer Information Service (CIS), aprogram of the National Cancer Institute(NCI), provides the latest and most accur-ate cancer information to the public andhealth professionals.

The UWCCC sponsors the North CentralRegion CIS based in Madison that servesWisconsin, Iowa, Minnesota, North Dakotaand South Dakota. The CIS celebrates itsSilver Anniversary in 2001, and the UWCCCis proud to be one of a very limited numberof cancer centers who have sponsored a re-gional office since the service began in 1976.

Nearly 12,000 residents called the CIS 1-800-4-CANCER phone number last yearfor information, resources and support.Three out of four callers either have canceror are a friend or family member ofsomeone with cancer.

For more informationPhone 1-800-4-CANCER

or 1-800-422-6237

Hours 9 a.m.-4:30 p.m. (Monday-Friday)

Web Site http://cis.nci.nih.gov/


Cancer Connect and Cancer Information Service

Ruth Bronston (left), a member of the Cancer Connect staff, assists Liz LaBella and her husband, Joe with the CancerHelp Touchscreencomputer in the patient education/consultation room in the CancerClinic, UW Hospital and Clinics. This system enables patients to learn ontheir own about currently available resources.

T

Cancer

The UWCCC established its Cancer ControlProgram more than 25 years ago and theresearch priorities of the program haveevolved to meet the changing profile ofcancer in the community. Over the pastdecade, the number of cancer controlresearchers in the program has more thandoubled, and the scope of the research hasbroadened to include a greater focus onpopulation sciences, including epidemiologyand behavioral science. Today the CancerControl and Population Science Programencompasses the full range of cancer controlresearch, from basic science aspects of cancer etiology (causes and origins) tosymptom control and quality of life amongcancer survivors.

The mission of the Cancer Control andPopulation Science Program is to understandthe causes and distribution of cancer inpopulations and support the development andimplementation of effective interventions.Research focuses on epidemiology andsurveillance, tobacco control, quality of lifeand pain and symptom management, andhealth communications.

Our first aim is to study the causes anddistribution of cancer using Wisconsin as apopulation laboratory. These epidemiologyand surveillance studies range from etiologystudies of modifiable risk factors tosurveillance studies to investigate geographicvariations in cancer rates. The cornerstone ofthese studies is the Wisconsin CancerReporting System, a mandatory registryestablished in 1976. The large-scale case-control studies of breast cancer etiology, ledby Dr. Polly Newcomb, have identified therelationship between modifiable exposures—alcohol consumption, physical activity,lactation, diet, exogenous hormone use—and cancer risk.

Control

C A N C E R C O N T R O L & P O P U L A T I O N S C I E N C E

The second aim of our program is toinvestigate clinical and policy interventionsto prevent tobacco-related cancers. In late1999, Dr. Michael Fiore, director of theCenter for Tobacco Research andIntervention, received a TransdisciplinaryTobacco Use Research Center grant fromNCI/NIDA. This five-year, $9.9 million grantcenters on the theme, “Relapse: LinkingScience and Practice.” In addition, thisgroup researched and authored the Agencyfor Health Care Policy Research (AHCPR)Smoking Cessation Clinical PracticeGuideline, which provides evidence-basedguidelines for smoking cessation.

Additionally our program works to test theefficacy and effectiveness of interventionsdesigned to prevent cancer, improve pain andsymptom management, and enhance end-of-life care. Dr. Sandra Ward and colleaguesstudy the linkages between patients’ attitudesand beliefs about reporting pain, their use ofanalgesics, and their quality of life outcomes.David Joranson and colleagues published apaper in the Journal of the AmericanMedical Association that analyzed the trends

in medical use and abuse of opioidanalgesics. This study documented that theincreasing medical use of opioids to treatpain does not appear to contribute to anincrease in opioid analgesic abuse.

Our final aim is to develop effective healthcommunications strategies for cancerprevention, early detection, and treatment atthe individual and population level. Dr.David Gustafson, a nationally recognizedresearcher in informatics and patientdecision-making, has pioneered developmentof a “computerized health enhancementsystem” or CHESS. His current research inbreast and prostate cancer focuses oninternet-based applications and computeruse among elderly and low-income women.The North Central Cancer InformationService (CIS), located at the UWCCC,provides new opportunities forcommunications research.

The Cancer Control and Population ScienceProgram has evolved considerably over thepast decade, building on a foundation ofepidemiology, behavioral science, and healthservices research.

ResearchDr. Amy Trentham-Dietz andcolleagues have demonstrated thatthe risk of breast cancer increaseswith increasing bodyweight. Thesefindings have important impli-cations for the future as the prev-alence of obesity continues toincrease in the country.

Dr. Michael Fiore and colleagues inthe Center for Tobacco Researchand Intervention conducted land-mark research that compared theefficacy of sustained-release

bupropion (Zyban) versus nicotinepatch therapy in the treatment ofsmoking.

David Joranson also analyzed thetrends in medical use and abuse ofopioid analgesics. This study docu-mented that the increasing medicaluse of opioids to treat pain does notappear to contribute to an increasein opioid analgesic abuse in the U.S.

OutreachThe UWCCC operates the NorthCentral Cancer Information Service

(CIS), the 1-800-4-CANCERtelephone resource. (See page 7 formore details.)

GrantsDrs. Fiore and Patrick Remingtonare working closely with theWisconsin Tobacco Control Board topromote effective community-basedprograms and evaluate their effects.These efforts will contribute to thestate’s efforts to reduce the publichealth burden from tobacco use.

Drs. Dennis Fryback andRemington have recently receivedgrants from the NCI to developcomputer models to betterunderstand trends in breast cancer,and to help explain the reasons forvariation in cancer rates withinWisconsin.

AwardsDr. Fryback was recently appointedto the Institute of Medicine, theprestigious national advisory bodyto the federal government for issuesin health and medicine.

“Our job is to serve asthe final link betweenthe Cancer Center andthe community to putresearch findings intopractice to improve thehealth of all Wisconsinresidents.”

Patrick Remington, MD, MPHCancer Control and Population

Science Program Leader


& Population Science

P R O G R A M H I G H L I G H T S

T

CancerGenetics

The Cancer Genetics Program of the UWComprehensive Cancer Center began justthree years ago and now has evolved toinclude 25 faculty members in 13 depart-ments from Chemistry to Surgery. It bringstogether investigators, from across the entirecampus, who use genetics in the study of cancer.

Our first aim is to define pathways ofpathogenesis. Such pathways are definedexperimentally either by human cancerfamilies or by mouse models for particularcancer types. Dr. John Petrini in Geneticsstudies cancer predispositions established bydefects in the repair of double-strand breaksin DNA. Dr. Eric Sandgren in the UW Schoolof Veterinary Medicine is developing a mousemodel for ductal pancreatic neoplasia, at lastpermitting the experimental study of thisneoplastic pathway. The laboratories of Drs.William Dove and Peggy Farnham in theMcArdle Laboratory for Cancer Research andDr. Russell Jacoby in Medicine study intestinalneoplasia.

The second goal of the Cancer GeneticsProgram starts with a particular neoplasticpathway and then identifies factors thatmodify the efficiency of that pathway. Anumber of different investigations at UW-Madison are identifying modifiers for ocular,mammary, hepatic, pancreatic and intestinalcancer. An exciting recent observation hasemerged from the study of numerous geneticfactors that modify the incidence of intestinalcancer in susceptible mouse strains. In apaper published in Cancer Research in 2000,Dr. Robert Cormier and his colleagues in Dr.Dove’s laboratory found that a particular pairof resistance factors, each mild in effect,shows strong synergy when imposed together.This discovery mirrors cases in therapeutics

C A N C E R G E N E T I C S

where certain combinations of drugs are farmore effective than either drug alone.

The research challenge created by suchgenetic discoveries is to find what molecularsubstances are controlled by the geneticfactors of interest. The emergence in 2001 offull DNA sequences for the human and themouse presents concrete ways to learn whatmolecular substances synergize to generateresistance to cancer.

Our third aim is to expand the power ofgenetic profiling of normal and neoplastictissues, both in humans and in animalmodels. New avenues for high-resolutioncytogenetics are being explored by Dr. DavidSchwartz of Chemistry and Genetics, usingoptical mapping of the entire complement ofDNA isolated from a single interphase tumorcell. Further advances in automatablegenotyping are being developed by Dr. LloydSmith in Chemistry. Dr. Peggy Farnham usesimmunoprecipitation to study the tumor-associated patterns for the assembly oftranscription factors on chromatin. Dr. JulieWells and her colleagues in the Farnham

group have been able to analyze thesechromatin complexes in living cells.

Our program’s long-term goal is to developexperimental methods to deliver tumormodifying alleles in vivo, either directly totumors or to the microenvironmentsurrounding tumors. Dr. John Young inMcArdle is developing methods to transfergenes by retroviruses. His approach isparticularly pertinent in the context of asecretory phospholipase that modifies coloncancer growth in mouse models.

Over the coming decade, the Cancer GeneticsProgram aims to characterize geneticallylarge numbers of genes of interest in each ofWisconsin’s cancer patients. Methods arebeing developed on campus and at nearbybiotechnology companies to determinegenetic makeup efficiently. At least 20,000 newcancer cases are diagnosed each year in thestate of Wisconsin. Through the WisconsinOncology Network and the Cancer ControlProgram of the UWCCC, new genetic andgenomic capabilities can become available toeach of these patients and their physicians.

ResearchThe Dr. Peggy Farnham group has demonstrated the ability tocharacterize in living cells theprotein assemblies that regulategene expression.

The Dr. Eric Sandgren group hasdeveloped the first mouse model forhuman pancreatic cancer thatshares strong histological featureswith the human neoplasm.

The Dr. William Dove group hasfound a pair of genetic factors that

modifies the severity of intestinalcancer in mice only weakly, butwhich in combination almostcompletely suppress the disease.

OutreachDr. Dove, along with members ofhis research group, providedleadership for the firstinternational workshop on theexperimental analysis of coloncancer, held at the JacksonLaboratory in Bar Harbor, Maine.Faculty from Wisconsin, Vanderbilt,Washington University, and the

Paterson Institute (Manchester,UK), along with 17 advanceddoctoral students and postdoctoralfellows entering the field of coloncancer genetics and biology,worked together for a week.

GrantsA startup program grant (P20) inMolecular Imaging from theNational Cancer Institute has beengarnered by a team of Wisconsininvestigators headed by Dr. ThomasGrist (Medical Physics). Membersof the Cancer Genetics Program

will provide key biologicalresources for this grant (Drs.Bradfield, Dove, and Young).

AwardsDr. Dove was elected to theAmerican Academy of Arts andSciences in 2000, joining his recentelections to the Belgian RoyalSociety of Arts, Letter, and Sciences(1999) and the National Academyof Sciences, USA (1998).

“The only drug currentlyapproved for preventionof genetically inheritedcolon cancer—Celebrex—was studied andvalidated by work on the Min mouse at theUniversity of Wisconsin.”

William F. Dove, PhDCancer Genetics Program Leader



T

Cell Signaling

The Cell Signaling and Growth ControlProgram seeks to understand the signals thatgovern the proliferation and invasion ofmetastatic tumors. Based largely in the UW-Madison Medical School, the programprovides opportunities for basic scientists,postdoctoral fellows and graduate students onthe Madison campus to devote their expertiseto cancer research. These investigators arealso linked to colleagues in the biotechnologyindustry through an annual symposium, heldeach spring in conjunction with PromegaCorporation, Madison.

A central focus of the program are thereceptor assemblies in the plasma membraneof the cell, formed in response to encounterswith the specialized extracellular matrix,growth factors and hormones. This is acrucial area for study, because theseencounters allow the cell to “sense” itssurroundings, and govern whether the cellwill remain quiescent, or will proliferate,migrate or die. Program researchers usemolecular techniques to analyze how thereceptors assemble into functional complexesat the cell surface, and how they signal intothe cell interior through kinase cascades andGTP-regulated molecular switches. Using amouse model, Dr. Caroline Alexander hasfound that syndecans, which act as co-receptors with cell adhesion and growthfactor receptors, have a central role in theinduction of breast cancer by the wnt-oncogene. Dr. Paul Bertics has shown that theepidermal growth factor receptor tyrosinekinase forms a functional complex withadhesion receptors to initiate intracellularsignals; this is an exciting area of researchbecause of the natural mutations that areknown to occur in this receptor in breastcancer and in brain gliomas.

C E L L S I G N A L I N G & G R O W T H C O N T R O L

A second focus of the program is to under-stand how intracellular signaling pathwaysfeed back on the cell surface receptormachinery to regulate its activity. Dr. RichardAnderson focuses on a family of enzymesthat synthesize and modify membranephospholipids (phosphatidylinositol kinases).These specialized membrane lipids arerecognized by signaling molecules that arerecruited to the sites of membrane receptorsignaling. Dr. Anderson also represents acomponent of a National Cooperative DrugDiscovery Group for “Discovery of Targetsand Therapies in PhosphoinositideSignaling,”a new consortium to discovertherapeutic agents that target thephosphoinositide signaling pathways incancer cells. Dr. Fran Fogerty is using thefruitfly Drosophila for a genetic screen toidentify downstream targets of the bcr-abloncogene that could be targeted forintervention therapies for chronicmyelogenous leukemia and acutelymphocytic leukemia.

The program’s third focus is the nucleus,where signals emanating from the cellsurface converge to regulate genetranscription and the behavior of the targetcells. Dr. Peggy Farnham has devised anexciting new approach to directly visualizethe protein complexes on DNA that regulategene activity. Dr. Shigeki Miyamoto examineshow transcription factors, especially NF-kBfamily members, are activated and targetedin and out of the nucleus. Anticancer agentsthat cause nuclear DNA damage, inparticular double strand breaks, can initiatenuclear signaling through NF-kB, leading toexpression of anti-apoptotic genes.

In the coming years, the goal of thisprogram will be to identify and characterizenew mechanisms by which cellular behaviorand phenotype are governed by molecularencounters at the cell surface. Our goal willbe to apply this new information to the dis-covery of drugs that will combat the motilityand invasion of metastatic cells, or directthem down pathways leading to cell death.

OutreachCell Signaling and Growth ControlSymposium. The members of thisprogram joined with the SignalTransduction Division of PromegaCorporation for a day-longsymposium featuring new cancerresearch findings. This symposiumwas attended by over 100professors, postdoctoral researchersand students from laboratoriesacross the UW Campus andPromega. Poster sessions andpresentations focused on new

developments in mechanisms oftumor cell invasion and signaling.

Sponsored Seminars. This programcollaborated with the UW graduateprogram in Molecular and CellularPharmacology to invite inter-nationally-recognized cancerresearchers to discuss their work onthe Madison campus. Two suchexamples include talks by Dr.Filippo Giancotti from MemorialSloan-Kettering Cancer Centerdiscussing integrin signaling and

growth control, and Dr. RichardCerione from Cornell Universitywho spoke on a new role for theGTPase cdc42 in Cell GrowthRegulation.

ResearchDr. Caroline Alexander described anew mechanism in which adhesionreceptor syndecan-1 regulates thewnt growth factor signalingpathway in breast tumorformation.

Dr. Shigeki Miyamoto and co-workers demonstrated that theanticancer agent camptothecinactivates the NF-kB transcriptionfactor, attenuating the efficacy ofthe drug.

Dr. Paul Bertics found that anactive EGF receptor is necessary foractive cell invasion, providing acrucial insight into how growthfactor and cell adhesion receptorscollaborate to control cell invasion.

“Evidence that cellsurface encountersgovern whether a tumorcell remains dormant,proliferates or diesprovides exciting newopportunities for cancerdrug therapies at theUniversity of Wisconsin.”

Alan Rapraeger, PhDCell Signaling and Growth Control

Program Leader


& Growth Control


T

Etiology &

The Etiology and Chemoprevention Programhas evolved from a merger of the well estab-lished research efforts in carcinogenesis of theMcArdle Laboratory for Cancer Research andthe chemoprevention section of the UWCCC’sCancer Control Program. This programincludes 31 researchers from 14 differentdepartments across the UW-Madison campus.

The mission of this new program is todetermine the causes of cancer and thentranslate this knowledge to develop andevaluate drugs, vitamins or other agents totry to reduce the risk of or delay thedevelopment of cancer.

Specific aims of the program include:

1. To investigate the causes of organ-specificcancers including liver, colon, prostateand breast cancer.

2. To utilize the knowledge of geneticmutations that lead to specific cancers inorder to design new treatments andidentify markers that measure diseaseprogression and the effects of treatment.

3. To design and perform clinical trials toevaluate these new treatments andmarkers.

Both the McArdle Laboratory and the UWCCChave made seminal contributions to the areasof cancer etiology and chemoprevention. Mostimportantly, basic findings in cancer etiologyhave led to the development and clinicaltesting of both cancer chemopreventionagents and strategies. Our long tradition oftranslational research is being continued bycurrent members of this program.

E T I O L O G Y & C H E M O P R E V E N T I O N

Integrated research in the area of etiologyand prevention was started in the laboratoryof Dr. Harold Rusch, who was the foundingdirector of both the McArdle Laboratory andthe UWCCC. He studied UV carcinogenesisand was one of the early investigators tostudy the effects of calorie restriction oncancer prevention. Current members of theprogram continue this work on calorierestriction.

One of the most pivotal findings that directedmodern research into chemicalcarcinogenesis was provided by Drs. Elizabethand James Miller at the McArdle Laboratoryin the early 1950’s. They demonstrated thatmany environmental and xenobioticchemicals required metabolic activation tocause cancer. Several current members of ourprogram continue to study mechanisms bywhich chemical carcinogens are activated.

Drs. Roswell Boutwell and Henry Pitot wereamong the first investigators to studymultistage carcinogenesis in animal models.

Dr. Boutwell focused on the initiation-promotion model for skin cancer, and incollaboration with Dr. Ajit Verma, translatedknowledge gained from this model into thearea of chemoprevention. Another importantprevention strategy developed by the UWCCCwas the concept of the use of tamoxifen toprevent breast cancer.

More recently, members of our program havediscovered and are developing a novel classof chemoprevention agents, themonoterpenes, which originated in a basicscience experiment conducted by Drs.Michael Gould and Charles Elson. Based onthese data as well as the unique cellular andmolecular activities of this compound,clinical testing of the monoterpene perillylalcohol is underway.

Dr. Paul Carbone and colleagueshave completed accrual of morethan 300 patients into a definitivephase III trial of skin cancerprevention with DFMO. This drugwas developed in UWCCClaboratories.

Novel transgenic rodent modelshave been developed to facilitatepre-clinical development of agentsand strategies for skin cancer andbreast cancer prevention.

The detailed location of geneswhich have the potential to preventbreast cancer have been found in arodent model. In collaborationwith investigators in the CancerControl Program, DNA samples arebeing collected from breast cancercase control studies to investigatethese genes in patients.

Another area of focus is thegeneration and evaluation of newagents and intermediatebiomarkers for possible futureclinical trials. New biomarkers inboth breast and prostate cancer willbe generated using transcriptionaland post-transcriptional profiling.

In the future, our program willfocus on these dual role(therapy/prevention) compounds,such as protein prenylationinhibitors, angiogenesis inhibitorsand Vitamin D analogs. Work onthese compounds will greatlybenefit from parallel interests inthem by members of theExperimental TherapeuticsProgram of the UWCCC.

“UWCCC members havebeen instrumental in thelaboratory discovery andclinical testing ofchemopreventioncompounds includingtamoxifen, DFMO andperillyl alcohol.”

Michael Gould, PhDEtiology & Chemoprevention

Program Leader


Chemoprevention


T

Experimental

The Experimental Therapeutics Program ofthe UW Comprehensive Cancer Center beganin 1972 and now includes 44 members in 16departments within 5 schools.

The specific aims of this program are toidentify novel mechanisms of anticancertherapy and translate them to clinicalapplications, to perform initial humanclinical trials, and to move new therapies todisease specific settings. Angiogenesis, cellsignaling and Vitamin D analogs are theprimary areas for preclinical and clinicaldevelopment of new agents.

Angiogenesis research has been a major focusof this program. The UWCCC has conductednumerous clinical research studies usingangiogenesis agents, including the metallo-proteinase inhibitor AG3340, Thalidomide,Squalamine, Endostatin, 2-Methoxyestradiol(Panzem), SU5416 and Gleevac.

These studies incorporated many preclinical,clinical, imaging, and ex vivo assessments.Dr. Andreas Friedl (Department of Pathology)has performed preclinical Endostatin andbasic FGF binding studies to distinguishspecific binding sites and characteristics ofthese two naturally occurring proteins. Thelate Dr. Greg MacEwen and Drs. David Vailand Ilene Kurzman (UW School of VeterinaryMedicine) have performed companionanimal model studies of antiangogenesisagents such as Panzem and Endostatin genetherapy. Drs. James Thomas, Joan Schillerand George Wilding (Department ofMedicine) have performed phase I and IIclinical trials with these agents to identify themaximum tolerated dose, the optimalbiological dose, define toxicities, and todetermine efficacy of these therapies indisease specific settings. Imaging studies wereperformed by Drs. Fred Lee, Scott Perlman,Fred Kelcz and Thomas Grist (Department of

E X P E R I M E N T A L T H E R A P E U T I C S

Radiology) to assess angiogenesis and bloodflow changes in tumors. Dr. Robert Auerbach(Department of Zoology) developed ex vivoassessments to determine antiangiogenicactivity bioassays. Kendra Tutsch (UWCCCAnalytical Lab), Dr. Amy Harms (Biotech-nology Center) and Dr. Paul Hutson (Schoolof Pharmacy) used ELISA and Triple/QuadMass Spec analysis to evaluate thepharmacokinetic and pharmacodynamiccharacteristics of Endostatin.

The second area of research focus has beenpreclinical and clinical development of newagents that target cell signaling. TheEpidermal Growth Factor Receptor (EGFR)has been a specific focus. The aims of thistargeted research have been the developmentof a quantitative high throughput assay toassess potential kinase antagonists, toevaluate for differential inhibition of wild-type versus mutated EGFR and to apply thisinformation in the in vivo and clinical trialsettings. The high throughput screens aredone in the Center for Chemical Genomics.The Center synthesizes unique chemicallibraries, develops new miniaturized high

throughput screening technologies, evaluatesfor differential inhibition of wild-type versusmutated EGFR and develops surface-compatible screens. Several studies have beenconducted to evaluate different cell signalingtargets including NFkB, RAFtk inhibitors,FTIs, and EGFRtk inhibitors.

The third area of research focus has been thedevelopment and testing of Vitamin Danalogs. Since its discovery on the UW-Madison campus more than 80 years ago,Vitamin D has generated interest as apotential treatment for cancer. ExperimentalTherapeutics has conducted the first clinicaltrials of a Vitamin D analog, Hectoral,showing activity in advanced prostate cancer.

The program’s future plans include thetranslation of laboratory findings to clinicaldevelopment of new cancer therapies and theenhancement of communication among UW basic scientists, biologists, and cliniciansto bridge the efforts in all research areas.

Performed initial trials of theangiogenesis inhibitors, 2-Metho-xyestradiol and Endostatin, as wellas, Thalidomide and Squalaminein combination with chemotherapy.

Administered the first intravenousadenovirus specific to prostatecancer.

Conducted gene therapy trial of thep53 gene in adenovirus to lungcancer patients.

Drs. Mike Hoffmann and Brian Kaywere part of a team that obtained a$1.5 million grant from the Wm.Keck Foundation for the develop-ment of combinational chemicallibraries and robotic highthroughput screens.

Dr. Richard Love’s investigator-initiated RO1 supportedrandomized clinical trial ofadjuvant-surgical oopherectomtyplus tamoxifen in 709 Vietnameseand Chinese pre-menopausalwomen found the intervention tobe remarkably safe. It proved to beeffective in estrogen receptorpositive tumor-bearing patients andcost effective (estimate $350 peryear of life gained).

A number of new services orequipment have been secured.These include the BiotechnologyCenter’s Triple Quadropole MassSpec and MALDI-TOF, the UWCCCAnalytical Lab’s Single QuadropoleMass Spec, the Department ofBiostatistic’s microchip dataworkstation, the Department ofRadiology’s Micro CT scanner, andthe Biotechnology Center andDepartment of Chemistry’s HighThroughput Screening facility.

“Our recognition as oneof the strongest anti-cancer drug developmentprograms in the worldprovides Wisconsinresidents rapid initialaccess to the newestanticancer therapies.”

George Wilding, MDExperimental Therapeutics

Program Leader


Therapeutics


W

Human

We now know that viruses cause at least 15%of all human tumors throughout the world.Researchers in the Human Cancer Virologyprogram study members of each family ofviruses that cause cancer in people.

For example, between one-half and onemillion people develop liver cancer each year,which is caused by either the Hepatitis B virusor the Hepatitis C virus. Drs. Dan Loeb andPaul Ahlquist work with Hepatitis B virus andrelatives of Hepatitis C virus to understandhow they replicate so that we can block theirproduction and prevent their contributions tothe development of liver cancer.

Each year one-quarter to one-half of amillion women develop cervical cancer that iscaused by human papilloma viruses. Thereare more than 200 different papillomaviruses, but only a handful of them causecancer in people. Drs. Paul Lambert and PaulAhlquist work with the cancer-causingmembers of this family of viruses to elucidatethe peculiar viral information they introduceinto infected cells that fosters normal cellsevolving into tumor cells. Dr. Lambert andhis colleagues have also developed a precise,sensitive assay to discriminate betweendifferent papilloma viruses. This assay is nowbeing tested to determine if it can identifypatients with a potentially cancer-causingpapilloma virus.

The first human cancer shown to be causedby a virus (the most common childhoodcancer in Africa) is caused by Epstein-Barrvirus. This virus also causes a carcinoma inthe post-nasal space that is prevalent inChina, half of Hodgkin’s lymphomas in this

Cancer

H U M A N C A N C E R V I R O L O G Y

country, and lymphomas in immunocom-promised people throughout the world. Drs. Bill Sugden and Janet Mertz are studyingthe Epstein-Barr virus to elucidate themechanism by which it induces infected cellsto proliferate. It is this virally inducedproliferation that contributes to the infectedcell becoming a tumor. Dr. Sugden andcolleagues have characterized one viralprotein expressed in all Epstein-Barr viraltumors which, when inhibited, leads to celldeath. This understanding forms the basis fordeveloping an anti-tumor therapy specific forthese viral tumors.

In addition to revealing the mechanisms bywhich viruses predispose cells to evolve intotumors, members of the Human CancerVirology program are dissecting the routes bywhich viruses enter cells. Dr. Teresa Comptonstudies both human cytomegalovirus, whichcan cause severe infections in patientsreceiving chemotherapy and Kaposi’ssarcoma virus which causes its namesake

cancer. Dr. John Young studies retroviruses,which can infect and cause cancers intractable animal models and people. Thesetwo researchers, by illuminating the stepsdifferent viruses use to bind to and penetrateinto cells, are identifying targets to preventviral infection and thereby prevent theirassociated cancers.

Specific viruses target specific cell types. Dr. Young, by understanding exactly how anavian retrovirus enters a cell, has developedmethods to target a derivative of this virus toselected human cells. This selective targetingmay provide a means to kill some classes oftumor cells. Dr. Curtis Brandt is developingderivatives of the herpes simplex virus, whichcan infect neurons in people, as atherapeutic tool to treat tumors in the centralnervous system.

ResearchDr. Paul Ahlquist’s research groupfirst identified an intracellular hostfactor that contributes to the abilityof a positive-strand RNA virus tocopy its genes. This has importantimplications for understandingvirus infections and for developingantiviral drugs, particularly toviruses such as Hepatitis C, a causeof human liver cancers.

Members of Dr. Paul Lambert’slaboratory have shown that theexpression of some papilloma viral

oncoproteins in human cervicalcancers may contribute to theresistance of those tumors toradiation therapy, an insight thatmay drive improvements to currenttherapies.

Dr. Bill Sugden’s research grouphas provided new understandinginto the mechanisms of replicationin Epstein-Barr virus-associatedhuman tumors, with the goal ofidentifying viral targets for anti-viral and anti-tumor drugs.

Dr. John Young and his colleaguesprovided important new insightsinto how retroviruses enter cellsand developed novel approaches toenhance viral entry. Theseapproaches may permit targetingof human tumors with suicidalviruses.

OutreachIn the past year, program membershave organized severalinternational meetings includingthe Retroviruses meeting, theEpstein-Barr virus meeting, the

annual meeting of the AmericanSociety for Virology, and the DNATumor Viruses meeting.

AwardsIn 2000 Dr. Curtis Brandt receivedthe Marjorie Margolin Prize fromthe Retina Research Foundation,and Dr. Bill Sugden was named anAmerican Cancer Society ResearchProfessor.

“Our research at theUniversity of Wisconsin-Madison not onlyteaches us how virusescause cancer in peoplebut someday will showus how to treat thosecancers.”

Bill Sugden, PhDHuman Cancer Virology

Program Leader


Virology


T

Imaging &Radiation

The Imaging and Radiation SciencesProgram is focused on improving earlydetection and staging of cancer as well asdeveloping strategies to improve outcomes ofpatients treated with radiation. Ourgroundbreaking achievements include:

Tomotherapy. This program is led by Dr.Rock Mackie, who heads a multidisciplinaryteam of investigators. The world’s firstclinical tomotherapy unit was installed at UWHospital in February 2001 (see image to left).This technology integrates advances inhelical CT imaging with precisionradiotherapy.

The prototype will initially be utilized for workin non-biological systems, and subsequentlyin tumor-bearing pet animals in collaborationwith the Veterinary School. Human trials areexpected to begin later this year.

This technology affords unprecedentedaccuracy in the delivery of radiotherapy aswell as in the verification and adaptation ofan ongoing course of radiation treatments toensure that normal tissues are protected to thefullest possible extent. Because of the highlyprecise localization of radiation, it is possibleto deliver more radiation in a daily fraction,reducing the overall treatment duration.

Overcoming Radiation Resistance.Two clinical trials are focusing on theobjective of overcoming intrinsic tumorradiation resistance. Both focus on uniquemolecular targets, exploit innovative biology,and are large phase III randomized trials.

Dr. Paul Harari, utilizes antibody C225 incombination with fractionated external beamradiation therapy in patients with head andneck cancer. Dr. Harari’s laboratory hasidentified that the epidermal growth factorreceptor is overexpressed in most patients withhead and neck squamous cell carcinomas.

I M A G I N G & R A D I A T I O N

After preliminary testing, a large multi-centerphase III trial is now underway. Of key significance is the observation that the EGFRpathway blocade with radiation may have animpact in several other human tumors,including lung cancer, brain tumors andothers.

Dr. Minesh Mehta is involved in anotherunique international phase III multicenterrandomized trial, exploring Motexafin-Gadolinium (M-Gd) with daily radiationtherapy for brain metastases. This cancerafflicts over 100,000 Americans annually andrepresents an important cause of cancermorbidity and mortality. The outcome withtraditional therapy is relatively poor, andbased on prior laboratory and clinical work,this trial is focusing on M-Gd as a drug toinduce futile redox cycling in cancer cellsexposed to radiation therapy, therebyenhancing their apoptosis rate.

Cutting Edge Laboratory Research.Dr. Steve Howard’s laboratory exemplifies theongoing search for unique agents that canmodulate the radiation responsiveness ofseveral human tumors. Dr. Howard is

investigating Perillyl Alcohol (POH),developed by Dr. Michael Gould. POH, whencombined with radiation therapy, substantiallyenhances cell kill.

Innovative Imaging Agents. Dr. JameyWeichert leads an innovative laboratoryprogram that develops and evaluates cellspecific contrast agents. This past year, hisparticular focus was on phospholipid ethers,which are specifically taken up and concen-trated in tumor cells and rapidly removedfrom normal cells. NM404 is in humantesting and will be evaluated for safety.

Methods for Early Detection ofCancer. Several investigators researchinnovative methods for early detection. Dr.Susan Hagness is currently exploring highfrequency microwave mammography. In aunique set of experiments, her group hasdemonstrated that signal characteristics ofnormal breast tissue differ from those of bothbenign and malignant breast tumors. Thishas allowed her to begin a series ofexperiments to develop a clinically usabledevice for microwave mammography.

ResearchLed by Drs. Rock Mackie andMinesh Mehta, the world’s firstclinical tomotherapy prototypedevice has been constructed andinstalled and clinical research isnow underway.

The fastest accruing phase III brainmetastases trial testing a novelradiosensitizer, Motexafin-Gadolinium has been completed.(PI: Mehta)

A major phase III trial evaluating anovel radiation modulator, C225 (amonoclonal antibody to the EGFreceptor) is nearing completion.(PI: Harari)

Dr. Mark Ritter’s lab has identifiedseveral key molecular markersproviding prognostic informationfor prostate cancer.

Dr. Steve Howard’s lab hasdemonstrated that radiosensi-tization of glioma cells usingPerillyl Alcohol is mediated

through enhanced apoptosis,through Fas-ligand upregulation.Clinical trials are being developed.

Dr. John Fowler’s team hasdemonstrated that prostate cancershave very low alpha-beta ratios,leading to the design of a newgeneration of clinical trials.

OutreachClinical outreach services,including translational research,continue at four outreach sites:Beloit, Wausau, Freeport andManitowoc.

An innovative breast brachytherapyprogram has been developed.

GrantsA Program Project grant (PO1),focusing on tomotherapy has beenvery favorably reviewed by the NIHand funding is anticipated.

A startup program grant (P20) inmolecular imaging has beenawarded, led by program memberDr. Thomas Grist.

“We are extremely excitedthat the first tomotherapyunit has been installedat UW Hospital after 10years of research andplanning. Developed atthe UW, this technologywill revolutionizeradiotherapy.”

Minesh Mehta, MDImaging & Radiation

Program Leader



T

Immunology

The Immunology and ImmunotherapyProgram has a long history of integratingbasic laboratory discoveries and novel clinicalapplications and research. The programincludes 34 investigators, workingcollaboratively on basic and clinically appliedcancer immunology research in order toprovide improvements in cancer prevention,diagnosis and treatment. Our goal is tounderstand how the immune systemrecognizes cancer and use this knowledge tocreate strategies for effective cancer treatmentand prevention.

Our first aim is to clarify the mechanisms thatimmune cells and molecules use to recognizecancer and initiate an anti-cancer immuneresponse. Dr. Miroslav Malkovsky has identi-fied a novel immune cell, the gamma/delta Tcell, and found it has an innate capability torecognize tumor cells and other abnormaltissues. He is identifying the molecular signalsthat trigger these important cells. Drs. M.Suresh and David Watkins are evaluating howT cell receptors recognize molecules onabnormal cells, and how the molecules of themajor histocompatibility complex regulatethese T cell recognition events.

Our second aim is activating antitumorreactions through vaccine development,including the creation of “gene therapy”based vaccines. Drs. Alexander Rakhmilevichand David Mahvi have been evaluating theuse of Interleukin-12 (IL-12) genes to induceimmunity against tumors growing in mice.Dr. Malkovsky’s lab has shown that insertingheat shock protein genes into tumors inducesa strong antitumor response by the mouse’s Tcells. These are but two of several examples ofthe translational application of landmarkwork done by Dr. Jon Wolff, who showed howtransfer of “naked DNA” is an effective meansto perform cellular “gene therapy.”

I M M U N O L O G Y & I M M U N O T H E R A P Y

A third aim involves the use of monoclonalantibodies to recognize cancer and activatereactions that destroy cancers. Dr. MatyasSandor’s lab is investigating the mechanismsthat antibodies use to trigger molecularpathways of cell death. Dr. Jackie Hank isusing novel genetically engineered antibodiesthat have been linked to immune activatingmolecules, like Interleukin-2, to bind totumor cells and activate cancer destructionby inducing immune cell function throughIL-2 receptors.

The final two aims of our program translatethese basic biological observations intoeffective treatments for patients with cancer.First, these novel treatments are being testedextensively here by our veterinary oncologistswho are using several forms of gene therapyand engineered proteins to induce antitumorimmunity in companion animals withcancer. These patients are benefiting fromgene therapy vaccination studies that wereled by the late Dr. Greg MacEwen (1943-2001). Dr. MacEwen’s legacy is anoutstanding team of veterinary oncologists

who are pursuing novel gene therapy vaccinestudies (Dr. Ilene Kurzman), cytokine basedimmunotherapy (Dr. Stuart Helfand), andintegration of immune treatments withconventional chemotherapy (Dr. David Vail).

Finally, our clinical immunotherapyprogram has been at the forefront of testingcytokines, monoclonal antibodies, and genetherapy based immunizations as treatmentsfor adults and children. Drs. Sondel andMark Albertini are testing a novelmonoclonal antibody that is geneticallyengineered to contain IL-2. Dr. Mahviperformed Wisconsin’s first clinical genetherapy trial, in which he immunizedpatients with a tumor vaccine consisting oftheir own genetically modified tumor cells.Dr. Albertini performed a gene therapyvaccine study for melanoma patients inwhich a novel gene gun delivery system wasused to directly immunize patients with thegene for the gp100 melanoma antigen.

ResearchDr. Miroslav Malkovsky’s group hasidentified the molecular signalsthat activate gamma/delta T cells,and has shown the importance of aheat shock protein in makingcancer vaccines more effective.

Drs. Alexander Rakhmilevich, MarkAlbertini and Paul Sondel haveshown that immunizing with gm-csf DNA can increase the efficacy ofDNA based cancer vaccines in mice.

Dr. Paul Sondel’s group has shownthat the level of histocompatibilitygene expression on tumor cellsdetermines whether antibodieslinked to IL-2 will destroy tumorsin mice using T cells or NK cells.

Clinical trialsDrs. David Mahvi and MarkAlbertini performed the firstclinical gene therapy trials inWisconsin, and the first cancergene therapy trials nationally totest a novel gene gun technology.

Dr. Greg MacEwen demonstratedthe efficacy of gene therapyimmunizations in dogs withmelanoma, providing themethodology for Dr. Mahvi’sclinical studies.

Through a national consortium,Drs. Paul Sondel and MarkAlbertini initiate the first US test ofof engineered antibodies linked toIL-2 in melanoma patients and inchildren with neuroblastoma.

OutreachUWCCC immunotherapyinvestigators (Drs. Mahvi, Albertini,Sondel, and Joan Schiller) areactive in leadership of nationalimmunotherapy trials throughclinical trial cooperative groups inthe areas of neuroblastoma, lungcancer, melanomas and sarcomas.

“The antitumor efficacyof immunotherapy incanine cancers developedat UW-Madison hasallowed the clinicaltesting of novelimmunotherapies inchildren and adults withcancer here at the UWand in national studies.”

Paul Sondel, MD, PhDImmunology & Immunotherapy

Program Leader


& Immunotherapy


Program LeadersCommitteeDaniel M. Albert, MDGeorge T. Bryan, MD, PhDPaul P. Carbone, MD, DSc (Hon.)Paul M. DeLuca, Jr., PhDDavid L. DeMets, PhDWilliam F. Dove, PhDNorman R. Drinkwater, PhDMichael N. Gould, PhDJanet Greger, PhDKyungMann Kim, PhDE. Gregory MacEwen, VMDMinesh P. Mehta, MDJohn E. Niederhuber, MDHenry C. Pitot, MD, PhDAlan C. Rapraeger, PhDPatrick L. Remington, MD, MPHPaul M. Sondel, MD, PhDJames A. Stewart, MD

Bill M. Sugden, PhDSandra E. Ward, PhDJane Wegenke, BSGeorge Wilding, MD

External AdvisoryCommitteePaul Calabresi, MD (Chair)

Brown University School of Medicine

John Coffin, PhD Tufts University

James Cox, MDM.D. Anderson Cancer Center

Russell Hilf, PhD University of Rochester Medical Center

Ralph Hruban, MD Johns Hopkins University

Peter Jones, PhD USC/Norris ComprehensiveCancer Center

Albert LoBuglio, MD University of Alabama atBirmingham ComprehensiveCancer Center

Frank McCormick, PhD, FRSUniversity of California, San Francisco Cancer Center

Sara Perkel, MS National ComprehensiveCancer Center Network

Jasper Rine, PhD University of California,Berkeley

Steven Rosen, MD Northwestern University, Robert H. Lurie ComprehensiveCancer Center

G. Marie Swanson, PhDMichigan State UniversityCancer Center

George Vande Woude, PhD Van Andel Research Institute

Daniel Von Hoff, MD, FACP Arizona Cancer Center

Ralph Weichselbaum, MDUniversity of Chicago CancerResearch Center

Advisory BoardMembersDonald AndersonMarilyn AndersonDeEtte Beilfuss-EagerH. Mel BensteadGeorge BryanSandra Schwartz BryanPaul CarboneMary CarboneDiane Craig ChechikGloria EtterIlene FielkowJune FranklinJohn FrautschiAl GoldsteinSherry GoldsteinMary Lou Birkett GoodfriendJoanne HaertleForrest HartmannHans HellandMarjorie HellandGeorge IckeBarbara KilgoreTom KilgoreKevin KochNancy KreilickPhyllis LeachTerry LiermanCharles LoefflerMarian LoefflerChristine McHughKathy MosherLinda NielsenBill NitzkeLouise RuschDonald P. RyanSusan VeatchHelen Whitman-ObertMary WickhemAnne WolmanMartin Wolman

Senior LeadershipFrom left to right: George Wilding, MD, Associate Director–Clinical Programs; Norman Drinkwater, PhD, Associate Director–Laboratory Programs; Jane Wegenke, Associate Director–Administration; John E. Niederhuber, MD, Director; and Patrick Remington, MD, MPH, Associate Director–Cancer Control

L E A D E R S H I P A N D M E M B E R S


Cancer Center MembersPaul G. Ahlquist, PhDElaine T. Alarid, PhDDaniel M. Albert, MDMark R. Albertini, MDCaroline M. Alexander, PhDCatherine I. Allen, PhDB. Lynn Allen-Hoffmann, PhDThomas S. Anantharaman, PhDHenry A. Anderson, MDRichard A. Anderson, PhDM. Elizabeth Atkinson, MDRobert Auerbach, PhDBehnam Badie, MDHoward H. Bailey, MDTimothy B. Baker, PhDPaul J. Bertics, PhDChristopher A. Bradfield, PhDCurtis R. Brandt, PhDTara M. Breslin, MDEmery H. Bresnick, PhDReginald C. Bruskewitz, MDGeorge T. Bryan, MD, PhDRichard R. Burgess, PhDWilliam J. Burlingham, PhDPaul P. Carbone, MDSuresh R. Chandra, MDRichard J. Chappell, PhDHerbert Chen, MDSteven S. Clark, PhDJames F. Cleary, MBBSKelly H. Clifton, PhDTeresa Compton, PhDMark W. Craven, PhDCharles J. Czuprynski, PhDJune L. Dahl, PhDOnofre T. DeJesus, PhDHector F. DeLuca, PhDPaul M. DeLuca, Jr., PhDRobert I. DeMars, PhDDavid L. DeMets, PhDKenneth B. DeSantes, MDGelsomina DeStasio, PhDCarol A. Diamond, MDJeffrey A. Douglas, PhDWilliam F. Dove, PhDNorman R. Drinkwater, PhDRichard R. Dubielzig, DVMCharles E. Elson, PhDWilliam E. Fahl, PhDPeggy J. Farnham, PhDJason P. Fine, PhDMichael C. Fiore, MD, MPHFrances J. Fogerty, PhDJohn F. Fowler, PhDAndreas Friedl, MD

Dennis G. Fryback, PhDSamuel H. Gellman, PhDJames E. Gern, MDKennedy W. Gilchrist, MDMichael N. Gould, PhDDaniel S. Greenspan, PhDAnne E. Griep, PhDThomas M. Grist, MDElizabeth A. Grosen, MDDavid H. Gustafson, PhDSusan C. Hagness, PhDMajed M. Hamawy, PhDJacquelyn A. Hank, PhDLawrence P. Hanrahan, PhDPaul M. Harari, MDEllen M. Hartenbach, MDVictor M. Haughton, MDColleen E. Hayes, PhDSusan M. Heidrich, PhDJohn P. Heiner, MDStuart C. Helfand, DVMF. Michael Hoffmann, PhDMary C. Horne, PhDSteven P. Howard, MD, PhDPaul R. Hutson, PharmDAnna Huttenlocher, MDGuilherme L. Indig, PhDRussell F. Jacoby, MDDavid F. Jarrard, MDColin R. Jefcoate, PhDDavid E. Joranson, MSSWDouglas E. Jorenby, PhDBrad S. Kahl, MDWeiyuan John Kao, PhDCharles B. Kasper, PhDDavid A. Katz, MDBrian K. Kay, PhDPatricia J. Keely, PhDFrederick Kelcz, MD, PhDMary L. Keller, RN, PhDLaura L. Kiessling, PhDKyungMann Kim, PhDBruce S. Klein, MDJill M. Kolesar, PharmDMichael R. Kosorok, PhDIlene D. Kurzman, EdDGlen S. Kwon, PhDPaul F. Lambert, PhDPaul O. Larson, MDDiane R. Lauver, RN, PhDFred T. Lee, Jr., MDMary J. Lindstrom, PhDDaniel D. Loeb, PhDWalter L. Longo, MDRichard R. Love, MDE. Gregory MacEwen, VMD

T. Rockwell Mackie, PhDErnest L. Madsen, PhDPeter A. Mahler, MDDavid M. Mahvi, MDMiroslav Malkovsky, MD, PhDJames S. Malter, MDGerard J.D. Marriott, PhDLaurence J. Marton, MDYousif H. Matloub, MDDonna O. McCarthy, PhDMarilyn A. McCubbin, RN, PhDMinesh P. Mehta, MDLorraine F. Meisner, PhDJanet E. Mertz, PhDMary Elizabeth Meyerand, PhDMonte Dean Mills, MDCharles A. Mistretta, PhDShigeki Miyamoto, PhDTimothy D. Moon, MDAmy R. Moser, PhDDeane F. Mosher, MDR. Timothy Mulcahy, PhDDaniel L. Mulkerin, MDDaniel Muller, MD, PhDChristopher J. Murphy, DVM, PhDStephen Y. Nakada, MDPolly A. Newcomb, PhDMichael A. Newton, PhDRobert W. Nickells, PhDRobert J. Nickles, PhDJohn E. Niederhuber, MDT. Michael Nork, MDTerry D. Oberley, MDC. David Page, Jr., PhDBhudatt R. Paliwal, PhDMichael W. Pariza, PhDDonna M. Paulnock, PhDWalter W. Peppler, PhDScott B. Perlman, MDMary Ellen Perry, PhDDonna M. Peters, PhDJohn H.J. Petrini, PhDHenry C. Pitot, MD, PhDArthur S. Polans, PhDTomas A. Prolla, PhDDiane M. Puccetti, MDRonald T. Raines, PhDAlexander L. Rakhmilevich, MD, PhDNimmi Ramanujam, PhDAlan C. Rapraeger, PhDPatrick L. Remington, MD, MPHMark A. Ritter, MD, PhDH. Ian Robins, MD, PhDJoseph R. Robinson, PhDMarjorie A. Rosenberg, PhDJeffrey Ross, MD

Michael L. Rothschild, PhDArnold E. Ruoho, PhDFrancois Sainfort, PhDM. Shahriar Salamat, MD, PhDEric P. Sandgren, PhD, VMDMatyas Sandor, PhDJoan H. Schiller, MDJulian C. Schink, MDLinda A. Schuler, PhDDavid C. Schwartz, PhDGurbax Singh Sekhon, PhDRonald C. Serlin, PhDGary R. Shapiro, MDJude W. Shavlik, PhDLewis G. Sheffield, PhDNader Sheibani, PhDEileen P. Smith, MDLloyd M. Smith, PhDMaureen A. Smith, MD, MPH, PhDPaul M. Sondel, MD, PhDGary A. Splitter, DVM, PhDRichard A. Steeves, MD, PhDJames A. Stewart, MDBill M. Sugden, PhDM. Suresh, DVM, PhDSanthanam Swaminathan, PhDBruce R. Thomadsen, PhDJames P. Thomas, MD, PhDJames A. Thomson, VMD, PhDAmy Trentham-Dietz, PhDPatrick A. Turski, MDDavid M. Vail, DVMLynn Van Ummersen, MDAjit K. Verma, PhDSandra E. Ward, PhDDavid I. Watkins, PhDJamey P. Weichert, PhDRichard H. Weindruch, PhDGeorge Wilding, MDEliot C. Williams, MD, PhDJon A. Wolff, MDJon Pointon Woods, MD, PhDRobert D. Woodson, MDNing-Sun Yang, PhDJohn A.T. Young, PhDJames A. Zagzebski, PhD

The UW ComprehensiveCancer Center bringstogether the researchefforts of more than 200 faculty from 44 departments and 10 schools on the UW-Madison campus.

Each gift enables us to come closer to a cure. Donors and giftslisted on the following pages arefrom January 1, 2000 through December 31, 2000.

$100,000 & above Donors CaP CUREJohn J. FrautschiYvonne A. Gardiol Estate

$10,000–$99,999 DonorsDonald & Marilyn AndersonAnonymousCindy CrawfordKathy S. DeanRoger & Jeanne DeMerittDonald J. DoyleGolf for Eric and a CureSteven C. Leuthold Family Foundation

Our Hope of BurlingtonMargaret Schultz EstateAnn S. SimsT.E.A.M.S. Tomorrow’s Hope, Inc.Varian Medical SystemsEdward & Marguerite Vollbrecht, Jr.

$1,000–$ 9,999 DonorsADAC LaboratoriesThomas & Carolyn AgardAlexander Charitable FoundationAlma Doten Trust AgencyWilliam & Margaret AmendAmgen, Inc.Analysis Group, Inc.AnonymousDr. & Mrs. Gene Armstrong Dean J. ArnoldJoyce E. AtkinsonSteven Bach & Frances Van Nevel-Bach

Gerald & Kathleen Barbian Barnes & Noble, Inc.Barron Community Fund, Inc.Allan & Paulette Beerkircher Benstead & MacVicar FundH. Mel Benstead, Jr. Bristol-Myers SquibbChoose Hope, Inc.Condon Oil CompanyLouise M. ConklinMary Lee CozadFrances Cremer

JP Cullen FoundationGeorge & Dorothy DanlyPeter & Susan DavisEmmett J. DoerrWilliam & Joanne DoppstadtDousman Snow Troopers, Inc.Jeanne M. DoyleRoger N. DuhlEDSBarry J. Eichelkraut EstateLucille B. FarberFred FensterBarbara J. FinneganGenzyme CorporationRebecca C. GilsonAlbert & Sherry GoldsteinDebra GoldsteinDonna S. GorskiRoy GradeMary F. GrangerOlga GrkavacEdward & Nancy HansonRobert T. HartyRobert M. HauserMichael R. HeadingtonNelson & Vera Hicks CharitableFoundation

Charles & Julia HowellPearl S. HunkelPhilipp L. Hunkel Memorial FundFrances W. HurstGary & Elizabeth HurstIntegrated TherapeuticsPaul & Charlotte JaegerPeter P. JanssenRonald & Karen JensonMrs. R. Bernal JohnsonMr. & Mrs. Robert W. Johnson Brian T. KayeJohn M. KellyTerry & Mary KellyDaniel C. KettlerSally Killoran Lois J. KilmerKyungMann Kim &

Youngsook LeeMr. & Mrs. Timothy B. KincannonEugene KorbKris & Penelope Kubly Robert KyleGary & Beth LevertonIrving & Dorothy LevyLaura L. LindenLippe Taylor, Inc.

Charles & Marian LoefflerMadison Top CompanyOscar G. MayerEugene F. MayernickEmily B. McKayRobert & Janet MillerTerry MillerMineral Point Community ChestMorry & Lorraine MitzCharles & Carolyn MowbrayNational Rifle AssociationThomas & Regina OberlinPatrick W. O’LearyRobert & Lois OlsonOncology.comOne Fund Barron County, Inc.Nancy P. OrbisonGary L. OverboePanvera CorporationRichard & Louanne PauleyJanice D. PennauHarold & Jane PerlmanKenneth & Janet Pike Erwin Plesko & Joann Six-PleskoTommy & Karel RallLoeta C. ReedResearch and Diagnostic SystemsElliott J. ResneckJoan T. RichtsmeierRamona Robb TrustWanda L. RoodSafari Club InternationalWendell SagendorfScott & Peggy Sampson Charitable Fund

Marjorie SchmidtPeter & Colleen SchmitzGary SchulzeCarolyn P. SchwartzJames A. SchwertfegerKenn B. SheltonPhilamae SonntagJoseph & Jamie SteuerSteven & Susan StoddardMary Kay StrachotaGeorge & Catherine TesarJulius C. TeubertDavid & Delia TittleUnited Way of Delavan-DarianUW Hospital & Clinics James M. Van GrinsvenPaul & Lois Van NevelSusan E. VeatchLeone VoigtWalter J. Vollrath, Jr.Duard & Dorothea Walker

D O N O R S A N D G I F T S

Ross Romenesko, 15 (right), spoke at High Point Church,Madison during the UWCCC’s spring Cancer SurvivorsWeek. Ross, pictured with his parents Jeff and Tina, wasdiagnosed at the age of 6 with Burkitt’s Lymphoma, a rareform of cancer. He, with his mother, has written a bookbased on the poem he composed during his cancerexperience, “I Had a Tumor and It Wasn’t a Rumor.”

John & Jacalyn WarczakLaurence & Frances WeinsteinMervyn & Anita WeissMark & Carla WestcottMary WickhemWisconsin Dells Area United FundGail Leslie WurtzlerLorraine S. Zoborowski

$500–$999 DonorsPeggy AhlgrenMary Ann AllenJay F. AmmermanRoger & Ruth AmundsonMarcella E. BaggettMr. & Mrs. Theodore W. BattermanKent & Eileen BaumanBeverly BelauRobert & Donna BetzigHoward & Sandra BlauertThomas & Mafalda BosworthG.L. & L.V. Brunsell FoundationElburn C. BuckFrank E. BurgessLynn BurnetteRuth S. ButlerThomas & Elizabeth ButterbrodtDale & Alice CattanachCedar Grove Area United FundCivic LeagueDonald & Roberta ClevelandMarcus & Sheila CohenMarvin L. ConneyHoward & Alice CurlerRobert & Muriel CurryHarry & Ruth DavisDavid & Kathryn DeMetsJohn A. DuncansonDonald & Susan EmerichWilliam & Gail EnglerJohn J. FaturaMichael & Vivian FeenAnita Freeman EstateLori A. FullerDan & Cheryl GabrielsonGage CorporationEdith H. GaudioJames F. GinterJohn & Kimberly GoesJudith N. GreeneJoyce E. GustJoseph GutschenritterLoretta M. HamiltonLowell T. HansonForrest HartmannColleen HaslerFrank & Christine Heider

Quentin W. HeinVernon & Donna HellenbrandHarold B. HoltGary & Betty HurstNancy A. JamrozDonald & Ardys JankeA. Paul & Aileen JensenWilliam & Estella JohnsonThomas & Barbara KilgoreSharon A. KnoopEdward & Roberta KrinskyHarlan Kuehling & Janet O’NeillJames & Shirley LakeJennifer LaucksMr. & Mrs. Phillip LeeWilbert & Joanne MaassCharlotte Mac DonaldKevin Magee & Susan Connell-Magee

Arlene M. MargolisHoward & Marci MargolisMcFarland Spartan SharksEmily B. McKayMr. & Mrs. M.W. MedlenAdolph & Julia MikrutGuy & Judith MooreJohn OwenPackaging System of BarabooKathryn PalsGerald & Carol PetersenMr. & Mrs. Robert PloogRadiological Systems, Inc.Bruce H. RavidAnthony & Mary RichtsmeierMark & Karla RitterRichard & Nancy RoloffBarbara J. RubinPauline A. RuschViola SargentJanice SchefelkerPeter & Colleen SchmitzMilo & Harriet SchneiderNancy L. SchulzWinton & Ruth SchumakerDaniel L. SedlockRichard & Lynn ShallbergLinda SkaarGeorge W. SmallJames F. SmartCharles & Jean SmootsMary Ellen StaffordCatherine C. TannerJames & Carolyn TaylorEarl & Alice ThayerJane ThielkeTomorrow FundSarita F. Trewartha

Dr. E. Gregory MacEwen, 57,an internationally renownedveterinary oncologist andUWCCC member, died of aheart attack on May 12, 2001.

Dr. MacEwen was Professor and Head of theUW-Madison School ofVeterinary Medicine’sOncology Section. He wasinternationally recognized asa leader in the developmentof anticancer therapies. Dr.MacEwen, who joined theVet School faculty in 1983,served as Associate Deanfor Clinical Affairs from1987-1992, stepping downto allow for greater focus onhis oncology research.

"Dr. MacEwen was com-mitted to the School ofVeterinary Medicine, itsstudents, and the programin comparative oncology,which he built into the bestin the nation," Dr. DarylBuss, Dean of the School ofVeterinary Medicine said.

He was a pioneering leaderin the field of veterinaryoncology and the discoveryof novel and innovativecancer therapies for bothcompanion animals andpeople.

"He was a real giant, whohad so many things movingahead," said Dr. PaulSondel, Professor of Pedi-atrics and Human Oncologyand leader of the Immuno-therapy Program at theUWCCC. Dr. Sondel colla-borated with Dr. MacEwenon gene therapy andimmunotherapy researchthat bridged from canine tohuman studies. "He was notonly a glue, but anincendiary who built a fireand made things happen.

He was able to tie manydifferent disciplinestogether, including basicbiologists, veterinarians,medical oncologists, and avariety of disciplines ofveterinary and humanclinicians. Several studies oftreatment in children andadults with cancer havebeen built directly on Greg’sclinical research with cancerin companion animals."

Prior to his arrival at theUniversity of Wisconsin, hewas a staff oncologist atThe Animal Medical Centerin New York. He was boardcertified Diplomate in theAmerican College of Veter-inary Internal Medicine inthe specialties of internalmedicine and medicaloncology.

All of us who were touchedby him professionally alsodeveloped a deep andheart-felt personal relation-ship with this kind andgentle man. His untimelypassing will leave a tremen-dous void, however, hislegacy continues with thenumerous collaborationsbetween veterinaryoncologists and cancercenter members that heestablished and nurtured.

IN MEMORY OF DR. E. GREGORY MACEWEN (1943-2001)

$500–$999 Donorscontinued

Jerry & Denise TribbeyJorge A. ValleMr. & Mrs. Norton

Vande Poele, Jr.Robert & Elaine WaldeMariah A. WalkerNorma L. WamplerJohn & Joyce WestonJane R. WillWilliam & Daisy WilliamsonNan R. WilsonMr. & Mrs. Charles WoehrlPaul & Lynn WolfCalvin WolthauserMr. & Mrs. James N. YoungermanMr. & Mrs. Donald ZachSol ZaichickLois Ann ZeekMr. & Mrs. Donald Zimbric

$100–$499 DonorsAARP State Legislative CommitteeSeymour & Shirley AbrahamsonThomas P. AdasSharon L AdlerRonald & Sonja AhlertSanford M. Altschul Arnie & Sally Anderson

Edith AndersonHoward L. AndersonLouis & Marguerite AndersonLucille B. AndersonRita AndersonAnonymousRene D. Apps Arc, Inc.Thomas & Diane ArenbergJoan Ellis Arneson Robert & Barbara ArnoldDonald & Caroline Auler Gerald & Diane AulerLinda R. Ausse Jonathan & Susan AxelrodCarl & JoAnn BachhuberAnthony & Marlene BachimBadgerland Supply, Inc. Arlene BahlerCurtis & Sandra BakkEvelyn BakkeKenneth & Judith BalkinGerald & Kathleen BangoMerrill & Sylvia BanvilleRichard F. Barry James & Mary Ann BarteltTimothy & Clare BauerVivian M. Baumann Frieda BaxterPaul Bayer

Henry & Lorraine BeasterJoseph & Marge BeckGeorge & Mary BeckerMildred M. BeckerPeter Beckerman &

Kimberly A. Gross DeEtte Beilfuss-EagerDavid & Mary Bellamy, Jr. Craig & Christie BenderJanice R. BenderGeorge & Evelyn BenningWilliam & Lois BenzAbdulrouf & Natalie Ben-ZikriDavid & Jan BergeDouglas G. Berge Niles & Linda BermanRobert & Eva Lynn Berman Michael & Barbara BettigaHarold Bewick Marie BewickRuth Ann BeyersRobert & Ann BielefeldtKathleen Binger Ruth Blanch Ray J. Blaskey Beverly J. BlockDorothy E. Boatman Linda BochertRuth Bock Mr. & Mrs. Daniel Bojan

Joseph Bolan Mr. & Mrs. Albert BoltonJohn A. BolzRobert M. Bolz Jerome & Gloria BomierSteve & Nancy BooksArnold & Catherine BorcherBarbara K. BormanWalter BornerAlfred & Frieda BothumRichard & Connie Brachman, IIHoward & Caryl BremerMary Alice Brennan F. Anthony & Susan BrewsterRalph Von BriesenRobert H. Brigham Harland S. Bright Wesley & Sonja Brill William & Joan BrockPhillip & Marilyn BrockishDorothy E. Broder J.S. Broder David & Eleanor BrownPaul & Debra BruinsDennis & Barbara BrushG. Terry Bryan & Sandra Schwartz Bryan

Floyd A. BrynelsonPatricia BuchertHariette Bugbee Russell & Susan Bulgrin Jeannie A. Bultman Luella A. Burgess Robert & Katherine BurrisEdward & Lois BusbyGeorge & Judy BushMarilee J. Buska Larry & Sheryl ButsonGlenn & Clara ButtersRonald & Connie ButtersHelene S. Byrns Richard & Sandra BystedRichard & Marilyn CallawayDoris M. Carpenter Everett & Charlotte CassityBrenda K. Castillo Arthur & Beverly CastroWilliam Cerny, Sr.George & Faye ChallonerR. Keith & Emily ChapmanChase Manhattan Bank-SyracuseDiane C. ChechikRamon & Janet ChesnerMike & Susan ChildersWalter & Marilyn ChristiansenPeter C. Christianson


Since 1998, the 24-hour Tomorrow’s Hope Walk Fest in Jefferson, WI has raised over$210,000 for the UW Comprehensive Cancer Center. More than 1,000 walkers participatedin the 2001 Walk Fest, held June 22-23, 2001 at the Jefferson High School Athletic Field.

Martin & Lisa ChristoffersonRaymond & Memee ChunColleen A. Clary Kelly & Mayre-Lee CliftonHannah CohenRobert & Corine CohnRobert & Patricia CollinsRobert D. Colvin Michael & Kathy ConnollyJames & Zoe Connor John & Rosanne CookEugene & Rosalind CookeGeorge & Nancy CopeJohn & Judy CoppMaribeth CousinGerald CribbenElvin & Nancy CrispellGerald & Phyllis CrohnJoseph CuccioGerald & Kay CullenKenneth & Rose CumminsRuth E. Curtiss Marine & Shirley DableLouis & Shelley D’AgnoloHerbert & Brenda DahlmanBette DalebrouxBlair & Patricia Dalton Robert & Donna DarlingDavid & Paula DarrMr. & Mrs. Harry DavisDEC International, Inc.Helen M. De Groot Donald & Dorothy Deininger Mary Jo Demeza Diane M. Dempsey Joseph Denise Albert & Marion DeppelerRichard & Nancy DeraufDorothy R. De RoseAlfred & Bernice De SimoneMark & Leah DesingSally J. DeSoniaDavid & Julie DewittKurt & Kathleen DeyGus DeZoetenJohn & Susan DickensDonald & Claryce DierschkeRalph DillonYvonne Dimucci Mary Di NovoAlfred & Helen DiotteJohn & Nancy Dirlam Thomas & Joy DoepkeRichard P. Dolan Robert L. Dolezal Gloria J. Donsing

Richard & Suzanne DoppMarvin DorakRobin DouthittCharles J. DoyleDoylestown CharitiesGary & Kimberly DraegerHarold & Mary DrecktrahBrent & Michele DrenckhahnMildred R. DrostScott & Nanette DryburghKazimierz & Margaret DubickiHubert J. Dunn Loyal & Bernice DurandAnne L. Durcan Kenneth & Janelle DvorakDwaine D. Dvorak Michael & Susan EaganJudith Earling Paul & Constance EberlyRobert & Grace EcklandRosemary Ehr Sherwyn & Edith EhrlichThomas & Carol EhrsamRay EibenCharles H. EisLaurence EisemanJames & Jan EisnerJane M. Eisner Charles ElliottWilliam ElmanJames & Lynne EmerickJudy Engelke Leon & Shirley EpsteinRosalind EpsteinEric & Marilyn EricksonRandall & Susan EricksonMark EtzelRichard & Betty EvansKeith & June Eytcheson, Sr. Ralph & Judith FabriciusJames & Leslie FarmerRobert & Doretta FeatherstonWilliam & Colleen FeistBetty & Sidney FelderDiane Felsted-Jones Charles H. Fenske R. FerrisCharles & Nancy Fetter, Jr.Marilyn Feuling Ronald & Joanne FiedlerKendall & Shirley FingerFinova Capital CorporationPhilip & Janice FisherFred & Erna Fix Allen FlemingJohn M. Flesch

Les & Janet FloeterGene & Sandra ForstnerRolland & Barbara FoxA.J. & Marian FrancourJune Franklin Frances T. Frazier Byron & Janet FrenzMargaret A. Fridley Michael Best & Friedrich Leo & Frances FrigoHarlan & Leona FriskeMarvin & Beatrice FruthJudith E. Frye James L. Fullin Jesse & Wendy FurrerLeola R. GabelSamuel J. GabeltStewart & Liliane GaltKarl & Jennifer GapinskiRamona A. GasserGerald & Betty GastJohn & Lisa GastJames GaugertMr. & Mrs. Donald D. Gay John Gent, Jr.David & Velma GeraldsonRussell E. GessnerEdward & Patricia GibsonGiddings and Lewis Foundation Thomas & Beth GieseKennedy Gilchrist & Heidi WildeJames & Vicki GilsonGitlin & Gitlin Thomas & Rachelle GladbachWilliam & Julie Gladbach

Glen Hills United Fund Charles & Janice GoergMarilyn Gohr Kenneth & Sandy Gold Nerma GollinDonald & Yvonne GottschalkThomas & Roberta GradeKaete GranickGeorge GrkavacMark GromanMr. & Mrs. B. H. GrommesGSF Mortgage CorporationMary K. Guay Joseph & Sandra GueradGeorge & Anita GurdaGurnee CapeThomas & Mary Haak-FrendschoWilliam & Harva HachtenHeidi HaeberliRuben & Ramona HagenCletus & Shirley Hahn John & Margaret HaiderPatricia Halasz Mr. & Mrs. William HalfmanMaureen HallJohn & Irma HallGeorge & Lois HallamEsther W. Halline Terry & Alice HamptonCarlton & Mary HansenMr. & Mrs. Charles R. HarrisTurner & Mary HarshawHenry & Virginia HartJohn S. Hart, Jr.Thomas & Elizabeth Hart


Together, Chris McHugh, Linda Nielsen and PaulaLundberg founded Choose Hope™, a company thatoffers a line of products marketed and designed bycancer survivors. A portion of all proceeds benefitscancer research and services at the UWCCC.


John & Mary Ann Hartzell Jean M. HarvathJoseph & Norma Harvath Philip & Barbara Harvey Luke Hattenhauer Harold & Lois HauffeThoms HayeRussell S. Hebb Leroy & Helen HebelJames & Edith HeereyDavid & Charlene Hein Eugene & Veryl HeinQuentin W. HeinRaymond & Barbara HeldtHans & Marjorie Helland Jill HellerMarsha HellerEllen Jane Henderson Phillip & Suzanne HendersonLloyd A. Hendrickson Peggy HendricksonRobert & Marjorie HenkelDonald & Elizabeth HenningsJohn & Elizabeth HenricksenRosemary HerAnne W. Herb Gregg & Susan Herman Mark & Patricia HerrlingJohn P. Hess Mark & Robin HessefortDuncan Highsmith Rexford & Enid HoffmanWilliam C. Hogan Donald & Mary Hoida Earl & Jean HoldorfShirley A. Holler George Hollfelder

Vernon & Jean Holzer Honda Federal Credit UnionArnold J. Hope James & Joan HorsfallCarolyn D. Horton Ann R. Hoske William & Susan HotzAlbert & Lois HoughTimothy & Judith HowaldHomer L. Howard Richard HowarthJames HoytDavid & Debra HuberShaun & Tracy HuxfordCharles & Joyce HydeIdeal Packaging Group, Inc.Dale & Elinor IhlenfeldtGordon & Geraldine IscheDonald JabasNora E. JacobsonDeborah Jaeger Paul J. JaegerAlfred & Gladys JeahnVictor & Christine JensonDoris Johnson Elsa H. JohnsonJohn & Carol Johnson, Jr. Kenneth & Marilyn JohnsonMillard & Mary C. JohnsonCarol J. JohnstonJames & Joan JonesLee & Rosemary JonesConard & Susan JostadRobert & Martha Judd, Jr. Richard Z. Kabaker Brad S. KahlJames & Carolyn Kalk Thomas & Phyllis KanterNick Kapsos, Jr.Robert & Marilyn Karnas

Virginia KarstaedtKristine E. Kaski Harry & Arlene KatzeJoseph & Gladys KauffmanCarol F. Kaufman Marvin & Iva Kaune Marcella J. Kautza Patrick & Mary KelleherPatricia Keller Keller Family Charitable Trust Edward G. Kelley Robert J. Kennedy Family Paul & Peggy KentThomas & Ruth KentNicholas & Donna KernDavid A. Kershner Donald & Jacquelyn KildsigHenry Kimberly, Jr William & Virginia KingzettKenneth KliebardNeil & Christine KniselyWilliam D. Knox Denise Knutson Lois J. Koenig Theodore M. Koenigs Wayne & Patricia KoesslJames & Dolores KohnKimberly KolkAvis KolpinJoseph Korich Donald & Jean KoskinenC.E. & Patricia KozarekKimberly Kraft Grace Krajco Kris & Kathleen KramerAl KrausGerald & Margaret KrebleinNancy KreilickPaul & Mary KremkauJohn & Joan Kreul Jacquelyn Kriewaldt Katherine Krno Frank & Christine KromenakerHarold KromreyJerry & Karen KuehnMargaret J. Kuehni Robert KuenyRaymond & Felicia KunaLyle & Helen KurtzJerome H. Kuypers Rob La MacchiaKathryn C. Lamboley Melita E. Lambrecht TrustGordon & Margaret Lamont Violet A. Landsness Frank A. La Pointe

Charles LarsenDaniel & Martha LarsonDick & Wendy LarsonRobert & Ilene LarsonJennifer L. Laucks Mary E. Leach Phyllis LeachDonald H. Lee George Leedle Michael & Jeanne LefebvreRoy A. Lembcke Janet C. Lemke Ruth E. Lenovich Hugh & Gladys LewisRussell F. Lewis, Jr.Lawrence & Diane LichsteinJohn T. Lillejord Patricia LinsmeyerMr. & Mrs. John M. Linton John D. Lippitt Paul & Joanne LippittRoger & Barbara LippittWilliam & Dorothy Little, Jr.George & Mavis LoescherMarilyn R. Lohman Sara LongEdgar & Vilja LorenzsonnClarence G. Lorvig Mr. & Mrs. David LoveClark & Barbara LowryLowville Charities Fund Robert LozottePaul & Tracy LuberJoseph & Jean LuceyLarry & Jeanne LucierRobert & Dorothy Luening Donna D. Luessman Gary A. Lukken James & Christine LutzRobert & Bernice LynchJane LyonsEdward & Margaret MaasLynn & Eva MaddozErnest & Helen MadsenClara R. MageeDavid & Christine MahviMichael & Diane MaloneyEugene & Kathleen MandJames & Dorothy ManleyDorothy A. Mann Bruce J. Manthey Ameilio & Cheryl MarcolongoDonald & Blanche Margolis Steven & Teresa MarineGloria MarinoIda Marshall

Cassandra (l.) andAllison Trask, twindaughters of UWCCCClinical ResearchAssociate Diana Trask, participated inMadison’s 4th AnnualKomen Race for theCure®, Saturday, June 2, 2001. Despitecold temperatures, rainand wind, 6,000participants helpedraise more than$200,000.


Henry & Marguerite MatensMatlen Silver Group Christine MayerAva Marie Mayers John & Joyce McAnellyMarilyn McArdleNellie McCannonJoseph & Marian Mc CarthyDonald B. Mc Comb Vera V. Mc Comb Richard & Janice Mc CormickAnna McCoyEdward & Barbara Mc CulloughJames & Cornelia Mc DermottTerry & Christine Mc DonaldRobert & Verda Mc FarlaneAlex & Louise Mc GilvrayPatricia McGovernMichael J. Mc Manus Howard & Nancy MeadeMilan MecklenburgGregory & Linda MeierIrmgard F. MetzHarold & Norma MetzenPaul & Elise MeyerRobert & Carolyn MilamJeffery & Susan MillerJill MillerRobert & Nancy Miller Mr. & Mrs. Urban MillerWilliam & Iris Miller Chad & Donna MilneJames & Rita MitchellJames & Mary Ann MitchellThomas & Kelly MitchellMichael ModlWayne & Barbara MohrVernon & Jean MolbreakPhillip MontgomeryGuy & Judith MooreTimothy & Linda MooreWarren & Lorraine MooreJean Morhauser Lee & Mari Lynn MoritzMichael & Judy MormanMorrick Concrete, Inc.Loren D. Mortenson Joseph R. Mortenson Linda M. MoyArlie & Maryalice MucksTimothy Muldowney & Jackie HankDouglas & Shirley MullenRichard & DeDe MunzSusan Z. Murphy Ray & Marilyn MyersWalter & Nancy Naab

Raymond & Mary Jo NajemNational Catholic Society of Foresters-IL

National Catholic Society of Foresters-WI

James & Rebecca NauglerMr. & Mrs. Michael T. NeeseSteve J. NelesenJohn & Shirley NelesenBarry & Jeanne NelsonStephen NelsonAndrea NeuCharles & Rachel NicholsHarold & Jeanette NicholsMary L. NiedermeierJohn & Lori NolanIsabel NorsmanStewart & Mary NorthJames & Phyllis NorthwayErvin & Rosemarie NovacheckAmin & Ritha NyffelerTimothy & Mary O’BrienWilliam & Frances O’LearyJay & Nancy ObergJohn Oberstar Mary E. Odell Office of the GovernorDouglas & Betty Ann OldenburgRaymond Olson, Jr.Glenn & Lucille OnsagerPeter & Artie OrlikGilbert & Karla OrmsonWilliam & Earline OrndorffCraig & Catherine OstromOtsego Charity Funds Harold Ottenstein Joseph G. Otto Joseph & Mary OusleyNancy Outhouse Elizabeth C. PaddockTheodore & Mary PageThomas & Elaine PagedasGeorge PahiosRichard & Rachel PaullPaul’s BarMaxine L. Peckham James & Jeanne Pederson, Sr.Warren & Justine PedleyEdward & Judy Ann PeirickKen & Susan PelatzkeAlan PennRobert & Judith PenrodHenri & Patricia PensisGarry & Jeanne Perchik Charles & Barbara PerkinsMerle & Barbara Perkins

Ruth R. Persson Larry & Donna PetersDavid PetersonGerald PetersonLaurance & Phyllis PierceRonald & Jeanne Pike Peter C. Pikturna Arthur & Delores Pitas Virginia L Pitts Huberto R. Platz Frederick & Lois PolenzBetty J. Ponto Arthur & Elizabeth PopeJames & Jean PotterClemens & Audrey PrangeBradley & Sharon PressentinPrinting Partners Prism Mr. & Mrs. Robert PromenProvideo, LLC Richard Pump Uday & Supraja PunyamurthulaQuad Graphics, Inc. Quarter Century Club Charles & Patricia Quentel, III Douglas QuickRosemary RaceRB Royal Industries, Inc.David & Beatrice RadcliffeFrederick & Connie RadcliffeRichard & Larita Radtke

Robert & Elizabeth RaganRagsdale, Spitz & Reuschlein, S.C. Roger & Nancy RathkeGlen & Ardis RedekerRed Line Club George ReedDon & Carol ReederRobert L. ReeseJohn E. Reid & Associates, Inc.Herbert L. Reimer Winfield & Jean Reinemann, Jr. Robert & Jean RennebohmDiane M. RezagaholiThomas F. Ribar John & Shari RiceGerald & Lorraine RichterThomas Ries Kenneth & Joan RiggsGerald & Armella Ring Helen M. Ring Lee & Susan RiordanPeter & Carrie Ritz River Rats, Inc.Pamela Robbins Joan K. Robinson Rollan RoggensackPhilip & Ruth RollThomas & Martha RombergPaul RomlowRichard & Lois RossmillerRichard & Joan Rost


Former First Lady of Wisconsin, Sue Ann Thompsoncongratulated T. Rockwell Mackie at a reception unveilingthe new tomotherapy unit on January 24, 2001 at theCancer Center/UW Hospital and Clinics. The tomotherapymachine will deliver hundreds of precisely tailored radiationbeams in exactly the dosage and configuration needed tokill cancer, yet protect normal tissues in patients.


Sonia Sue Rotar Hershel & Arlene Rotter Kathryn RouseRobert & Geraldine RoykoRobert & Judith RubinFrederick & Patricia RuegseggerTyrone & Mary RumlowPatricia J. RuppLouise RuschHugh & Joyce RusselNancy C. RyanRobert & Brenda RyanRobert & Jennifer RyanBlaine & Florence SachtjenSaelens Corporation R. Thomas & Katherine SaetherJames & Barbara SainsburySaks, Inc.Randy & Nancy SanchezEmalou B. Sandsmark Daniel & Suzanne SapiroMarc & Carol SchatzRichard & Katherine SchefelkerEarl A. Schiefelbein Donald & Marilyn SchlaeferRoth & Jeanne SchleckMichael & Lisa SchmaltzAlex O. Schmidt Donald & Narcis SchmidtKrista M. SchmidtMartha M. Schmidt Paul & Cecilia Schmidt, Jr. Joseph E. Schmiedicke Dolly J. Schoenberg Margaret Schoonhoven

H. G. Schroeder James SchroederJohn & Kathryn SchulzFrieda M. Schurch Velma R. Schurch Judy Schuster Frederick & Deborah SchwartzAllan K. Scidmore Robert ScottGerald & Mary Ann SecorBarbara J. SeifrizKaren SellRoger & Margery Senn William & Elizabeth SewellMarjorie P. Shafton Doris M. ShainJames & Betty ShalbrackCarol ShierLaDell ShimniokMr. & Mrs. Neil ShivelyFrank L. Siegel Stephen & Lyn SillsClaude SimeD. O. & Shirley Simley Francis & Rosemary SimonisRoger & Linda SistermanEugene & Kathryn SkrochJohn & Herdis SkulasonCraig & Karianne SlettenGeorge W. Small Charles SmithClayton & Mary Jane SmithGordon & Shirley SmithKenneth & Robert SmithMargaret H. Smith Norma L. Smith Randolph & Patricia Smith

Weber & Carla SmithDavid O. Smrecek Bhupendra & Nirupama SoniBernard Soref Carol D. Sorg Jack & Helen SorgeJay & Lou Ann SpaanemJohn & Ruth Ann SpaayEloise K. Sparger Lilah & Leslie SprecherSpringvale Charities Fund Soly & Jean SrourThomas & Leona Stanek Henry & Kathie SteareDianne C. SteeleRichard & Elaine SteevesGeorge & Mavis SteilCharlotte A. Stein Marjorie StewartMargaret G. Stiles Marcella L. Stock Emily E. Stoddard Richard & Virginia StollWilbur & Lavae StraavaldsonW. O. Strawn David & Sandy StreetJohn & Patricia StreurC. Kendrick & Linda StrongHiroshi & Yuri SugiyamaFrederick C. SuhrD.M. Sumnicht Douglas & Annie SunbySundstrand CorporationRonald & Frances SwannRobert & Ann M. Sweeney, Sr.Leo & Patricia SweetLeonard A. Szudy

Marjorie J. Takton Tetsu & Kathlene TanimotoTod Tanner Harold & Ethel TarkowDorothy H. Taylor Lorena M. TeaschnerArnold TemteFred & Betty TerbilcoxTeresa Teachey Associates, Inc.Marilyn Terwilliger TLC of Wisconsin, Inc.Robert & Juanita ThomassonAndrew & Marian ThompsonBarbara J. ThompsonMr. & Mrs. Charles W. Thompson Marvin & Dolores ThompsonRonald & Marjorie ThompsonDennis & Joan Thomson Keith & Ruth ThorntonRae W. Thousand Mr. & Mrs. Robert R. Tollison Robert & Norma TrojanMrs. Guido Trombetta Agnes J. TrubshawSylvia M. Tustison Blair & Kathryn TysonLeonard C. Tysver Jon & Susan UdellUlla United Fund of Barron Township United Fund of MarionUnited Fund of Troy TownshipMargaret H. Van Alstyne John D. Van LiereJan & Barbara Van NessMichael & Mary VenaRuth & Harlyn VerhagePaul A. Vitullo Claude VollmerMary Jane Voss Richard B. Vowles Antons & Theresa VrublevskisMichael & Margaret WachtelErwin & Joyce WaedowErika J. WagnerRuth A. WagnerStuart & Natalie WaldoEdward & Marie WankeHarold J. WarmkeMark & Marilyn WarshauerWaterloo Senior High Student Council

Kenneth & Beverly WatsonLester & Karen WattersWilliam & Karen WeberWilliam J. WebsterFred & Elaine Wegner

Actress and Madisonnative Jill Eikenberry,breast cancer survivor, andher husband actor Michael Tucker spoke tomore than 300 individualsat a UWCCC CancerSurvivors Week event heldMay 17, 2001 at the Alliant Energy Center,Madison. Jill and Michael,who have been marriedover 20 years, travel thecountry to share theirjourney to recovery, fromthe viewpoints of patientas well as caregiver.


Frederick & Mary WehmeyerFrank & Patricia WeissJames & Ann WeissLarry & Amy Jo WeissJoseph & Sally WepferDavid & Sybil WestlakeMarsha L. WetmoreGail P. WhippleRussell & Jane WhitacreFlorence W. WhitefieldNeil WienkeAndrew & Melinda WilcoxMcAllister & Beverly WilcoxMrs. Richard Wilcox & FamilyWild Rose One Fund, Inc.Arline WilemanMark WilkeFrances M. WilkinsonRobert & Helen WilliamsonGerald & Judith WillieDavid & Elise WilsonJules M. WinnWisconsin Alumni Research Foundation

Wisconsin Cancer RegistrarsAssociation

Richard & Marilyn WolfJerry & Nancy WolfeRon & Barbara WolfeMartin & Anne WolmanJack & Joyce WoodPeter & Karen WoodJosephine O. WoodburyDouglas & Tracy WooleverDonald & Carol WorelWilliam & Mardelle WuergerPaul & Ruth Wuethrich Robert & Emma WustmannAlice YarabinecCeyril & Dora YelkDiana J. YoungEdwin H. YoungLouise A. YoungJoseph J. Zeimet EstateDonald & Cynthia ZimmermanLucille ZimmermanAlvin & Donna ZivenE. J. & Donna ZmolekErwin & Joan Zuehlke

We have made every effort to listall $100+ gifts received during2000. If your gift was inadver-tently omitted, or if there is anerror on our part, we apologize. Ifyou have any questions, pleasecontact the development office at(608) 263-1677.

In Honor ofSam BahlerDr. Howard BaileyDianne BingerGeorge T. Bryan, Jr.Kathryn Ann BryanGlenn ButtersJohn & Marianne CullenHumphrey Stuart DesmondRacquel FioreAlbert & Sherry GoldsteinMary E. Bryan HanrattyDick HeadingtonLloyd MuellerTracey NiederhuberLeonard & Zita SimutisDr. James A. StewartCarolyn TaylorNick & Barbara Zeppos

Honor gifts are given in memory of a loved one who isliving. A minimum gift of $100has been made in honor of theindividuals listed.

In Memory ofMatthew Adams, Jr.Joan AdasLydia AdduciNaomi AmmermanRuth AmundsonMuriel AndersonRaymond H. AndersonStewart AndersonJon AntonAnne ArnoldHollis AtkinsonDonald AulerDonald AxelrodJames N. BachmannKonrad William BakkRobert BarlassElizabeth BaxterAnn BeasterNorman BeckerAndy BenzmillerRay BlanchHoward BlauertJane BohnMerilyn BuckMertz BuckConnie E. BugbeeDale BultmanVanita ButtersAlice CattanachLouis Ciaccio, Sr.

Roberta ClevelandRobert CohnMary Allice ColvinJacqueline Conner-WolthausenEllen CoxJo Ann CraftDr. J. William Conklin CruzPatricia DaltonMae DarlingSally DearbornArlene DenkertKim DerringtonBetty DesingIneke De ZoetenJean DolanRobert A. DolezalRobert DraegerMarge M. DunnJean DvorakMyrna EibenBarry J. EichelkrautWilliam EricssonRichard EvansMarjorie FaitThomas FarberRuth FeenValmai FensterCyril FinneganSuzanne S. FischerErna Fix

Mary FullinStella GlinskiElmer GohrJorene & George GrabJack GraceyMargaret GradeWilliam GrangerValentina GrkavacFred GrosinskeClifford GustCletus HahnJoseph HalaszSteven HalversonMary HansonDorothy A. HappAnnette HauserMary HeadingtonEdith HeereyG. Robert HendersonGladys HenningsPhyllis HenricksonViolet HoeperJudy HoffmanRobert HollerJerry HowardMarjorie HowardHeather C. HrabovskyCharlotte JaegerDonald JankeMarlene Janssen


Through its various community outreach activities, the UWCCC provides life-enhancing cancer informationservices throughout Dane County and Wisconsin.Volunteer Breast Health Ambassador Brenda Gonzalezhighlights the importance of mammograms at locationssuch as the South Madison Health and Family Center.

In Memory of continued

Willard JohnsonKenneth KarlenRichard KaskiMarvin L. KauneArthur J. KautzaMatt KennedyChristopher KettnerBart KincannonTheresa KorthWilfred J. KrajcoElmo KriewaldtCletus KrollKarin KromenakerArthur KuehniLinda LageTarry LageMelita LambrechtKenneth LangbeckerLois LangbeckerHoward LarsonLaura LeedleBerni LenhertJohn LenovichDavid LiebergenAmy LingMartha LippittAlice LukkenDuane ManleyBlanche MargolisRobert MarinoVera McCombJames McCoyKathleen McGuireEvelyn MelbyeColleen MillerJames MitchellLloyd MuellerDr. Robert E. NajemIdell NesgaardYvonne OrmsbyDonna OverboeJanet OwenStanley W. PerssonGeorge PhalenMelvin PittelOrlo PontoJohn PotokarD.C. PressentinDory ResneckMary RichtsmeierCorinne RieckDavid RobbinsJoan P. RosenbergJohn W. RoweHelen RoykoPeter Rubin

Terry RumlowG. Irving SchefelkerAdeline SchiefelbeinMarnie A. SchmidtRoger SchmidtSue SchneckMilo SchneiderLorraine SchoonhovenLois SchulzeJohn SchutzGerald SchwennDon SeversonKathleen SeversonDarryl O. ShainAnne SimsLeRoy SimsJohn L. SmithJohn SovaMax SpargerRichard SteeleIrvine SteinJudy StittGarfield R. StockJoanne StonnelPatricia SyverudRichard TerwilligerBarbara ThompsonDr. Raymond ThompsonFred TrierMike TustisonKay Van GrinsvenFrances Van NevelJay VanSloanLaurabelle VinjieSuzanne M. VossIrvin WadsworthOtto R. WagnerMary WalkerG.D. WhitefieldDonald WilkeJudge Hubert L. WillFlorence WilleMaurice WilliamsStanley WilsonWilbert WiviottEric WolfeGloria WuethrichEmma WustmannNorman YackleJoseph ZeimetErich Ziemann

Memorial gifts are given inmemory of a loved one who isdeceased. A minimum gift of $100has been made in memory of theindividuals listed.

HighlightsFinancial


The generous contributors to theUW Comprehensive Cancer Centerpartner with us to support:

• Startup funding to establish researchprograms of new faculty

• Pilot projects to explore innovativenew research ideas

• Research professorships foroutstanding faculty

• Supplemental support for UW graduate training programs incancer research

• Cancer Connect—the UWCCC patientinformation service

• Regional, national and internationalresearch conferences

• Community outreach and educationprograms

• Purchase of major researchequipment to augment UWCCCshared services

$4

1997/98 1998/99 1999/2000 2000/01

$3

$2

$1

($ in

mill

ions

)

$1,6

54,0

87 $3,2

06,3

95

$2,9

80,6

35

$3,3

05,8

91

Annual Contributions to the UW Comprehensive Cancer Center

REVENUE

Federal Awards $ 9,579,593 56%

Industry Awards $ 3,196,897 19%

Contributions $ 3,305,891 19%

UW Medical School Support $ 744,108 4%

Other UW Support $ 423,842 2%

Services Rendered $ 427,111 3%

Investment Earnings -$ 656,101 -3%

Total Revenue $ 17,021,341

EXPENDITURES

Personnel $ 8,681,259 57%

Equipment $ 766,954 5%

Supplies and Other $ 3,274,839 21%

Indirect Cost Payments to UW $ 2,529,317 17%

Total Expenditures $ 15,252,369

Excess Revenue over Expenditures $ 1,768,972

National Cancer Institute (NCI) $ 32,034,000 41%

National Institutes of Health (NIH) $ 23,547,000 30%

National Science Foundation (NSF) $ 2,936,000 4%

Other peer-reviewed Awards (DOD, VA, FDA, etc.) $ 3,688,000 5%

American Cancer Society $ 798,000 1%

Other Awards (Federal and Industry) $ 14,358,000 19%

Total Research Support $ 77,361,000

(Includes research funds administered in home departments)


Funds Administered by the University of Wisconsin Comprehensive Cancer Center July 1, 2000-June 30, 2001

Research Support for all University of Wisconsin Comprehensive Cancer Center members July 1, 2000-June 30, 2001

WWhen you contribute to the UW Compre-hensive Cancer Center, you help ourorganization maintain its leading role ininnovative research initiatives, compas-sionate cancer care, and education for thepublic and health care professionals.

Your contribution enables our researchersto explore new ideas, purchase new tech-nology for effective cancer research, anddevelop better methods of diagnosing,treating and preventing cancer.

Funding for the Cancer Center’s research,outreach, and treatment programs is moreimportant than ever. There are many waysto support the UW Comprehensive CancerCenter:

Unrestricted Gifts are truly valuablebecause they provide the flexibility neededfor research to move quickly in unexpecteddirections and to swiftly pursue promisingclinical applications. Unrestricted fundsalso provide the resources to cover the costsof critical services not entirely financed byother support.

Restricted Gifts benefit specific programs of your choice. Funds may bedesignated for initiatives in specific re-search, patient care and educational needs.

Corporate Matching Gifts are anexcellent way to increase your givingpotential to the Center. For moreinformation, please contact your humanresources office or our development office.

Memorial & Honor Gifts allowcontributors to recognize loved ones in aspecial way. Memorial gifts are made inmemory of family members, friends, orcolleagues who have passed away. Honorgifts show someone in your life a measureof affection, admiration or gratitude. When

such gifts are made, a special notificationis sent to the family or the individual.

Major Gifts are a specific way forindividuals, organizations, corporations, orfoundations to contribute to the Universityof Wisconsin Medical School’s HealthStarCampaign. Funds from this campaign willbuild the Interdisciplinary Research Center,which will prominently feature the UWComprehensive Cancer Center andinnovative cancer research. Please call(608) 262-5252 for more information.

Other examples include purchasingresearch equipment, funding fellowship orresearch programs, sponsoring specialevents, or underwriting programs for thecommunity or health care professionals.

Planned Giving, in the form of giftannuities, charitable remainder trusts, ornaming the Center in your will, is also anoption. The UW Comprehensive Cancer

Center can also be named as a beneficiaryof retirement plans, trusts or life insurancepolicies. The Office of Planned Giving atthe University of Wisconsin Foundation canassist individuals in planning these gifts.Please call (608) 263-4545.

The University of Wisconsin Foundation isthe official fundraising and gift-receivingorganization for the UWCCC.

For more information aboutcontributing to the UW ComprehensiveCancer Center, please contact:

Ann Johnson UW Comprehensive Cancer Center600 Highland Avenue, K4/658Madison, WI 53792-6164

(608) [email protected]

Your Contribution is aCommitment to the Future

COPYWRITINGCraig Robida, UWCCCMichael Felber,

UW Health Marketingand Public Affairs

CONTRIBUTORSCaroline AlexanderRhoda ArzoomanianTania BanakKaren BlomstromRuth BronstonLynn BucherClaire CulbertsonWilliam DoveJulie FiersGayla Garlick-HansenPaula GoodeMichael GouldMark InmanAnn JohnsonMinesh MehtaJohn NiederhuberAlan RapraegerPat RemingtonBette SheehanTerri SmithPaul SondelBill SugdenJane WegenkeKathy WieseGeorge Wilding

PHOTOGRAPHYSutter PhotographyMary Langenfeld

COVER IMAGEAmy Dresen, UWCCC

Analytical Laboratory

SPECIAL THANKSDuane Gay

CONTRIBUTED PHOTOS HLM Design, p 4UW-Madison School

of VeterinaryMedicine, p 27

Tomorrow’s Hope, p 28Choose Hope, p 29Julie Ethridge, p 30The Capital Times, p 31

GRAPHIC DESIGNChristine O’Connell,

UW Health Marketingand Public Affairs

MORE INFORMATIONFor patient services atthe UW ComprehensiveCancer Center contact: Cancer Connect1-800-622-8922 or(608) 262-5223 or [email protected]

For information on the latest researchinitiatives, news andupcoming events, please view the UW ComprehensiveCancer Center’swebsite:www.cancer.wisc.edu.

COPYRIGHTINFORMATION© 2001 UW ComprehensiveCancer Center600 Highland AvenueMadison, WI 53792-0001(608) 263-8600www.cancer.wisc.edu

UW Health is the brand thatsignifies a patient-focused, three-pronged academic healthsystem supported by:

• University of WisconsinHospital and Clinics, wheremore than 12,000 cancerpatients are seen annually for diagnosis, therapy, follow-up care or second opinions.

• University of WisconsinMedical School, the UW-Madison campus home of the faculty members who do research, teach and provide patient care.

• University of Wisconsin MedicalFoundation, the academicgroup practice and clinicalfaculty of the UW MedicalSchool, including more than900 physicians who practice at 50 locations.

CC2531-0101P

The UW Comprehensive CancerCenter is one of only 40comprehensive cancer centersdesignated by the NationalCancer Institute, the lead federalagency for cancer research.

NCICCC®

university of wisconsin comprehensive cancer center · the prevention and cure of cancer. ... the...

Documents